≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Diabetes insipidus

DOID EFO Endpoint Browser PheWeb

E4_DIABINSIPIDUS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E23.2
  • Hospital discharge: ICD-9 — 2535
  • Hospital discharge: ICD-8 — 25390
  • Cause of death: ICD-10 — E23.2
  • Cause of death: ICD-9 — 2535
  • Cause of death: ICD-8 — 25390

2 out of 7 registries used, show all original rules.

354

4. Check minimum number of events

None

354

5. Include endpoints

None

354

6. Filter based on genotype QC (FinnGen only)

346

Control definitions (FinnGen only)

Control exclude
E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
E23
Name in latin
Diabetes insipidus

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1936 1022 905
Only index persons 1614 884 730
Unadjusted period prevalence (%)
Whole population 0.03 0.03 0.03
Only index persons 0.03 0.03 0.03
Median age at first event (years)
Whole population 43.88 45.33 42.11
Only index persons 42.57 44.24 40.55

-FinnGen-

Key figures

All Female Male
Number of individuals 346 214 132
Unadjusted period prevalence (%) 0.07 0.08 0.06
Median age at first event (years) 48.53 47.29 50.55

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
354
Matched controls
3540
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
326.3
307.7
269
34
E23.2
ICD-10 Finland
Diabetes insipidus
+∞
307.7
324
*
102
Kela drug reimbursment
Diabetes insipidus
+∞
262.3
218
*
H02AB09
ATC
hydrocortisone; systemic
53.9
183.3
109
29
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
98.7
90
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
1128.1
92.1
86
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
91.7
84
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
332.1
80.0
78
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
16.9
69.9
62
44
H03AA01
ATC
levothyroxine sodium; systemic
5.4
55.0
170
514
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
151.8
50.3
52
*
2535A
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Diabetes insipidus
+∞
40.4
38
*
R35
ICD-10 Finland
Polyuria
7.0
39.4
67
114
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
9.5
38.7
49
59
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
8.8
38.4
52
68
H53.4
ICD-10 Finland
Visual field defects
12.4
35.0
36
32
25390
ICD-8 Finland
Diseases of pituitary gland, Diabetes insipidus
+∞
35.0
33
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.2
30.6
72
165
R63.1
ICD-10 Finland
Polydipsia
74.9
30.5
34
5
H01AC01
ATC
somatropin; parenteral
+∞
29.6
28
*
XCK00
NOMESCO Finland
Perimetry
6.2
28.7
53
97
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
8.7
27.8
37
47
N05AN01
ATC
lithium; oral
8.3
23.3
32
42
301
Kela drug reimbursment
Growth hormone
+∞
23.2
22
*
D35.30
ICD-10 Finland
Craniopharyngoma
+∞
22.1
21
*
AA1AD
NOMESCO Finland
CT of head and brain
3.1
22.0
139
618
E87.0
ICD-10 Finland
Hyperosmolality and hypernatraemia
64.1
21.1
24
*
N25.1
ICD-10 Finland
Nephrogenic diabetes insipidus
+∞
21.0
20
*
D44.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pituitary gland
222.6
20.8
21
*
AA4BG
NOMESCO Finland
MRI examination of sella turcica with high intensity magnet
222.6
20.8
21
*
E23.05
ICD-10 Finland
Lack of TSH
+∞
18.9
18
*
E23.09
ICD-10 Finland
Pituitary insufficiency NOS
+∞
17.9
17
*
ZXC86
NOMESCO Finland
Use of endoscopic device
52.8
17.2
20
*
E23.6
ICD-10 Finland
Other disorders of pituitary gland
+∞
16.8
16
*
TAB00
NOMESCO Finland
Lumbar puncture
4.6
16.0
40
95
AA4DG
NOMESCO Finland
Very extensive MRI examination of sella turcica with high intensity magnet
+∞
15.7
15
*
E23.02
ICD-10 Finland
Neurosecretory dysfunction of the growth hormone
+∞
15.7
15
*
N03AG01
ATC
valproic acid; systemic, rectal
4.3
15.3
42
107
N03AX14
ATC
levetiracetam; systemic
6.9
15.1
24
37
L28
ICPC
Limited function/disability (L)
2.9
15.0
87
360
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.8
14.8
95
414
E89.30
ICD-10 Finland
Postprocedural hypopituitarism
+∞
14.7
14
*
E23.0
ICD-10 Finland
Hypopituitarism
+∞
14.7
14
*
WX882
NOMESCO Finland
High dependency care
12.8
13.8
24
20
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.9
13.6
75
300
E23.03
ICD-10 Finland
Lack of ACTH
+∞
13.6
13
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.9
13.3
74
298
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.3
13.3
54
181
N04BC06
ATC
cabergoline; oral
72.5
12.7
14
*
AA4CM
NOMESCO Finland
Extensive MRI examination of sella turcica with 3 Tesla magnet
+∞
12.6
12
*
E22.0
ICD-10 Finland
Acromegaly and pituitary gigantism
+∞
12.6
12
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.0
12.5
61
228
A12BA01
ATC
potassium chloride; oral
5.4
12.4
25
49
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
16.6
12.3
19
12
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
14.1
12.1
20
15
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
2.8
12.0
68
275
N05AH03
ATC
olanzapine; systemic
3.5
11.9
43
133
N05AA02
ATC
levomepromazine; systemic
4.6
11.9
29
67
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
5.2
11.9
25
51
R42
ICD-10 Finland
Dizziness and giddiness
2.4
11.8
100
493
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
11.6
97
475
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
3.4
11.6
44
141
E22.1
ICD-10 Finland
Hyperprolactinaemia
+∞
11.5
11
*
9350/1-C75.2
ICD-O-3
Craniopharyngioma, NOS, of craniopharyngeal duct
+∞
11.5
11
*
R53
ICD-10 Finland
Malaise and fatigue
2.3
11.2
116
623
N05BA01
ATC
diazepam; systemic, rectal
2.7
11.1
68
286
N05AF03
ATC
chlorprothixene; systemic
5.2
10.9
23
47
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.4
10.8
86
411
N05CD07
ATC
temazepam; oral
3.0
10.7
52
193
C02AC05
ATC
moxonidine; oral
4.6
10.7
26
60
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.2
10.7
117
641
N91.1
ICD-10 Finland
Secondary amenorrhoea
14.8
10.6
17
12
E23
ICD-10 Finland
Hypofunction and other disorders of pituitary gland
+∞
10.5
10
*
D35.31
ICD-10 Finland
Cyst in Rathke's pocket
+∞
10.5
10
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.2
10.5
44
150
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.6
10.4
69
302
N05AH04
ATC
quetiapine; oral
2.4
10.4
88
432
ZXC95
NOMESCO Finland
Use of surgical navigator
10.5
10.1
19
19
UKC02
NOMESCO Finland
Cystoscopy
2.6
10.0
63
269
G03FB08
ATC
dydrogesterone and estrogen; systemic
3.5
9.9
35
107
R51.80
ICD-10 Finland
Headache
2.4
9.9
82
398
E21.0
ICD-10 Finland
Primary hyperparathyroidism
56.6
9.7
11
*
A06AD11
ATC
lactulose; oral
2.6
9.6
60
255
25310
ICD-8 Finland
Diseases of pituitary gland, Panhypopituitarismus
+∞
9.4
9
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
+∞
9.4
9
*
R60.0
ICD-10 Finland
Localized oedema
2.7
9.3
56
233
WZC00
NOMESCO Finland
Treatment plan or consultation
2.0
9.2
148
928
U04
ICPC
Incontinence urine
3.8
9.2
29
82
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.7
9.1
30
87
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.7
9.1
52
211
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
19.2
9.0
13
7
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
8.9
179
1209
XCW99
NOMESCO Finland
Other investigative procedure of eye
2.8
8.9
48
188
ZYC01
NOMESCO Finland
Remote contact by phone
3.0
8.9
40
142
N39.4
ICD-10 Finland
Other specified urinary incontinence
2.9
8.9
44
165
N17.9
ICD-10 Finland
Acute renal failure, unspecified
4.6
8.7
21
48
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.9
8.6
26
71
J01MA12
ATC
levofloxacin; systemic
2.3
8.6
72
349
N06AX03
ATC
mianserin; oral
3.8
8.6
27
76
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
7.7
8.6
19
26
R33
ICD-10 Finland
Retention of urine
3.3
8.5
34
112
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.0
8.5
128
780
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
8.9
8.4
17
20
E23.06
ICD-10 Finland
Empty sella
+∞
8.4
8
*
22620
ICD-8 Finland
Benign neoplasm of endocrine glands, Pituitary gland and craniopharyngeal duct (pouch)
+∞
8.4
8
*
E23.3
ICD-10 Finland
Hypothalamic dysfunction, not elsewhere classified
+∞
8.4
8
*
2542
FHL
Transasal hypophysectomy
+∞
8.4
8
*
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.3
8.3
68
326
WX892
NOMESCO Finland
Monitored bed care
3.1
8.3
36
125
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
3.6
8.3
28
83
A41.9
ICD-10 Finland
Sepsis, unspecified
4.5
8.3
20
46
Z01.8
ICD-10 Finland
Other specified special examinations
2.1
8.1
93
513
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
7.9
63
299
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
6.6
7.8
19
30
R50.9
ICD-10 Finland
Fever, unspecified
2.3
7.8
65
314
UJF32
NOMESCO Finland
Coloscopy
2.1
7.8
96
542
WX402
NOMESCO Finland
General anaesthesia
2.1
7.7
93
520
XKD06
NOMESCO Finland
Physiologic investigation of micturition
4.7
7.7
18
40
N05BA04
ATC
oxazepam; oral
2.0
7.6
105
616
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.9
7.5
37
138
T36
ICD-10 Finland
Poisoning by systemic antibiotics
3.6
7.4
25
74
G47.3
ICD-10 Finland
Sleep apnoea
2.0
7.4
96
552
E27.2
ICD-10 Finland
Addisonian crisis
+∞
7.3
7
*
2273A
ICD-9 Finland
Benign neoplasm of other endocrine glands and related structures, Pituitary gland and craniopharyngeal duct (pouch)
+∞
7.3
7
*
E23.08
ICD-10 Finland
Hypopituitarism
+∞
7.3
7
*
E23.01
ICD-10 Finland
Isolated deficiency of growth hormone
+∞
7.3
7
*
25320
ICD-8 Finland
Diseases of pituitary gland, Chromophobe adenoma, pituitary
+∞
7.3
7
*
121
Kela drug reimbursment
Severe hypofunction of sexual glands
7.6
7.3
16
22
H47.2
ICD-10 Finland
Optic atrophy
20.5
7.2
10
5
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.0
7.2
95
549
N03AX09
ATC
lamotrigine; oral
3.1
7.2
30
102
SPAT1255
SPAT
Intravenous administration of medicine
3.2
7.1
29
97
A50
ICPC
General and Unspecified, Medication/prescr/renewal
4.0
7.1
20
52
OAB50, ,
SPAT
2.8
7.1
36
137
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.7
7.1
40
161
T99
ICPC
Endocr/metab/nutrit disease other
6.6
7.0
17
27
Z2446
NOMESCO Finland
Social worker
3.0
6.9
32
115
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.0
6.9
91
524
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
4.3
6.9
18
44
J01MA02
ATC
ciprofloxacin; systemic
1.8
6.9
138
912
WX408
NOMESCO Finland
General anesthesy, balanced
2.0
6.9
98
580
KA1AE
NOMESCO Finland
Kidney ultrasound examination
5.9
6.9
18
32
N06AX21
ATC
duloxetine; oral
2.3
6.8
58
282
G04BD04
ATC
oxybutynin; oral, transdermal
3.0
6.8
30
105
R55
ICD-10 Finland
Syncope and collapse
2.5
6.8
45
196
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.5
6.7
46
203
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
6.6
6.7
16
25
SPAT1262
SPAT
Handing over of treatment supplies
2.2
6.7
63
320
XF400
NOMESCO Finland
ECG with 12 standard connections
2.3
6.6
57
278
N30.0
ICD-10 Finland
Acute cystitis
2.1
6.5
67
351
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.4
6.5
23
70
G03DB01
ATC
dydrogesterone; oral
2.3
6.5
52
246
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.3
6.5
54
260
Y28
ICPC
Limited function/disability (Y)
71.1
6.4
7
*
G04BD12
ATC
mirabegron; oral
2.3
6.4
49
227
TKC20
NOMESCO Finland
Catheterisation of bladder
3.0
6.4
29
103
K90
ICPC
Stroke/cerebrovascular accident
6.8
6.4
15
23
F31.6
ICD-10 Finland
Bipolar affective disorder, current episode mixed
7.2
6.3
14
20
9350/1-C75.1
ICD-O-3
Craniopharyngioma, NOS, of pituitary gland
+∞
6.3
6
*
2532A
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Panhypopituitarism[PANHYPOPITUITARISMUS]
+∞
6.3
6
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.1
6.3
26
88
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.4
6.2
46
210
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
2.6
6.2
38
159
J01FF01
ATC
clindamycin; systemic
1.9
6.2
102
631
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
3.9
6.2
18
48
R56.8
ICD-10 Finland
Other and unspecified convulsions
3.1
6.1
25
84
C03CA01
ATC
furosemide; systemic
1.9
6.1
93
561
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.2
6.0
24
79
A28
ICPC
Limited function/disability NOS
2.1
6.0
63
332
R11
ICD-10 Finland
Nausea and vomiting
2.4
6.0
42
187

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Endocrinology
46 [38004485]
2.0e+00
3.2e+00
3.9e+00
—
3.8e+00
3.8e+00
3.2e+00
cases:18.07%
controls:2.82%
cases:27.95%
controls:1.56%
cases:13.66%
controls:0.31%
—
—
cases:23.75%
controls:0.69%
cases:46.93%
controls:1.95%
cases:45.96%
controls:3.39%
58
90
263
3100
90
50
232
3146
44
10
278
3186
—
76
22
244
3167
145
61
164
3066
125
94
147
2677
Neurosurgery
14 [38004459]
1.8e+00
2.6e+00
4.1e+00
1.0e+50
2.9e+00
2.7e+00
2.2e+00
cases:10.90%
controls:1.94%
cases:13.66%
controls:1.13%
cases:9.01%
controls:0.16%
cases:2.17%
controls:0.00%
cases:3.44%
controls:0.19%
cases:12.62%
controls:0.96%
cases:15.44%
controls:1.95%
35
62
286
3128
44
36
278
3160
29
5
293
3191
7
0
315
3196
11
6
309
3183
39
30
270
3097
42
54
230
2717
Outpatient Visit
OP [9202]
5.9e-01
1.3e+00
1.4e+00
5.2e+00
1.8e+00
1.8e+00
1.2e+00
cases:76.01%
controls:63.79%
cases:69.57%
controls:38.74%
cases:28.57%
controls:8.60%
cases:43.48%
controls:0.41%
cases:36.88%
controls:8.53%
cases:79.29%
controls:38.95%
cases:88.97%
controls:70.19%
244
2035
77
1155
224
1238
98
1958
92
275
230
2921
140
13
182
3183
118
272
202
2917
245
1218
64
1909
242
1945
30
826
hydrocortisone; oral, parenteral
H02AB09 [21602737]
2.3e+00
3.6e+00
—
—
1.0e+50
4.0e+00
3.4e+00
cases:11.84%
controls:1.32%
cases:15.84%
controls:0.50%
—
—
—
—
cases:9.69%
controls:0.00%
cases:20.39%
controls:0.48%
cases:25.00%
controls:1.12%
38
42
283
3148
51
16
271
3180
—
—
31
0
289
3189
63
15
246
3112
68
31
204
2740
Osmolality of Urine
2695-5 [3026782]
1.1e+00
2.6e+00
4.6e+00
—
—
2.6e+00
1.8e+00
cases:7.17%
controls:2.41%
cases:12.42%
controls:1.10%
cases:13.66%
controls:0.16%
—
—
—
—
cases:9.71%
controls:0.83%
cases:13.97%
controls:2.74%
23
77
298
3113
40
35
282
3161
44
5
278
3191
—
—
30
26
279
3101
38
76
234
2695
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
2.1e+00
3.6e+00
—
—
—
3.4e+00
3.2e+00
cases:8.10%
controls:1.10%
cases:10.25%
controls:0.31%
—
—
—
—
—
—
cases:13.92%
controls:0.54%
cases:24.63%
controls:1.30%
26
35
295
3155
33
10
289
3186
—
—
—
43
17
266
3110
67
36
205
2735
Internal Medicine
11 [38004456]
9.7e-01
1.8e+00
2.1e+00
—
3.2e+00
1.9e+00
1.5e+00
cases:35.20%
controls:17.08%
cases:29.50%
controls:6.32%
cases:9.01%
controls:1.22%
—
—
cases:16.56%
controls:0.78%
cases:30.42%
controls:6.43%
cases:47.06%
controls:16.17%
113
545
208
2645
95
202
227
2994
29
39
293
3157
—
53
25
267
3164
94
201
215
2926
128
448
144
2323
clozapine; oral, parenteral
N05AH02 [21604542]
2.4e+00
2.3e+00
2.1e+00
—
—
2.1e+00
2.3e+00
cases:2.80%
controls:0.25%
cases:2.80%
controls:0.28%
cases:2.17%
controls:0.28%
—
—
—
—
cases:2.27%
controls:0.29%
cases:2.21%
controls:0.22%
9
8
312
3182
9
9
313
3187
7
9
315
3187
—
—
7
9
302
3118
6
6
266
2765
pH of Serum or Plasma
2753-2 [3018418]
1.0e+00
1.5e+00
2.9e+00
—
2.7e+00
1.5e+00
1.6e+00
cases:9.03%
controls:3.45%
cases:8.07%
controls:1.97%
cases:5.59%
controls:0.31%
—
—
cases:5.94%
controls:0.41%
cases:9.06%
controls:2.21%
cases:18.38%
controls:4.44%
29
110
292
3080
26
63
296
3133
18
10
304
3186
—
19
13
301
3176
28
69
281
3058
50
123
222
2648
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
3.2e+00
—
1.0e+50
—
—
4.1e+00
3.7e+00
cases:6.85%
controls:0.31%
—
—
cases:2.48%
controls:0.00%
—
—
—
—
cases:10.68%
controls:0.19%
cases:12.50%
controls:0.36%
22
10
299
3180
—
8
0
314
3196
—
—
33
6
276
3121
34
10
238
2761
Polyuria
R35 [45539331]
2.0e+00
4.1e+00
1.0e+50
—
—
3.0e+00
1.8e+00
cases:3.12%
controls:0.44%
cases:10.25%
controls:0.19%
cases:3.11%
controls:0.00%
—
—
—
—
cases:3.24%
controls:0.16%
cases:3.31%
controls:0.58%
10
14
311
3176
33
6
289
3190
10
0
312
3196
—
—
10
5
299
3122
9
16
263
2755
Neurology
13 [38004458]
9.7e-01
1.8e+00
1.9e+00
1.0e+50
2.5e+00
1.9e+00
1.5e+00
cases:19.31%
controls:8.34%
cases:20.19%
controls:4.07%
cases:4.35%
controls:0.66%
cases:3.42%
controls:0.00%
cases:5.94%
controls:0.50%
cases:18.45%
controls:3.20%
cases:30.15%
controls:8.88%
62
266
259
2924
65
130
257
3066
14
21
308
3175
11
0
311
3196
19
16
301
3173
57
100
252
3027
82
246
190
2525
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
9.1e-01
1.6e+00
2.5e+00
—
2.7e+00
1.5e+00
1.4e+00
cases:12.77%
controls:5.58%
cases:13.66%
controls:3.22%
cases:7.45%
controls:0.63%
—
—
cases:7.50%
controls:0.56%
cases:12.30%
controls:3.10%
cases:25.00%
controls:7.58%
41
178
280
3012
44
103
278
3093
24
20
298
3176
—
24
18
296
3171
38
97
271
3030
68
210
204
2561
Office Visit
OMOP4822458 [581477]
1.2e+00
1.8e+00
2.0e+00
—
2.6e+00
1.5e+00
1.3e+00
cases:19.94%
controls:6.74%
cases:13.35%
controls:2.47%
cases:1.86%
controls:0.25%
—
—
cases:4.38%
controls:0.34%
cases:10.36%
controls:2.43%
cases:22.43%
controls:7.33%
64
215
257
2975
43
79
279
3117
6
8
316
3188
—
14
11
306
3178
32
76
277
3051
61
203
211
2568
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
3.0e-01
9.5e-01
2.4e+00
3.5e+00
2.1e+00
9.9e-01
5.6e-01
cases:27.41%
controls:21.85%
cases:33.23%
controls:16.11%
cases:27.64%
controls:3.47%
cases:8.39%
controls:0.28%
cases:19.69%
controls:2.95%
cases:35.92%
controls:17.30%
cases:45.96%
controls:32.77%
88
697
233
2493
107
515
215
2681
89
111
233
3085
27
9
295
3187
63
94
257
3095
111
541
198
2586
125
908
147
1863
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
8.8e-01
1.6e+00
2.7e+00
—
2.5e+00
1.4e+00
1.3e+00
cases:13.71%
controls:6.18%
cases:15.84%
controls:3.60%
cases:8.70%
controls:0.66%
—
—
cases:7.50%
controls:0.66%
cases:13.59%
controls:3.81%
cases:26.84%
controls:8.81%
44
197
277
2993
51
115
271
3081
28
21
294
3175
—
24
21
296
3168
42
119
267
3008
73
244
199
2527
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.9e-01
9.1e-01
2.3e+00
3.4e+00
2.0e+00
9.5e-01
5.2e-01
cases:27.41%
controls:21.97%
cases:32.92%
controls:16.49%
cases:26.40%
controls:3.50%
cases:8.07%
controls:0.28%
cases:18.75%
controls:3.01%
cases:35.60%
controls:17.59%
cases:45.22%
controls:33.02%
88
701
233
2489
106
527
216
2669
85
112
237
3084
26
9
296
3187
60
96
260
3093
110
550
199
2577
123
915
149
1856
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
1.7e+00
2.8e+00
1.0e+50
—
—
3.2e+00
2.3e+00
cases:4.05%
controls:0.78%
cases:4.04%
controls:0.25%
cases:1.55%
controls:0.00%
—
—
—
—
cases:5.18%
controls:0.22%
cases:8.46%
controls:0.94%
13
25
308
3165
13
8
309
3188
5
0
317
3196
—
—
16
7
293
3120
23
26
249
2745
Inpatient Visit
IP [9201]
7.2e-01
1.3e+00
2.4e+00
—
2.4e+00
1.8e+00
9.7e-01
cases:13.08%
controls:6.83%
cases:7.45%
controls:2.22%
cases:4.04%
controls:0.38%
—
—
cases:5.00%
controls:0.47%
cases:9.39%
controls:1.76%
cases:15.81%
controls:6.64%
42
218
279
2972
24
71
298
3125
13
12
309
3184
—
16
15
304
3174
29
55
280
3072
43
184
229
2587
Outpatient Hospital
22 [8756]
6.2e-01
1.5e+00
2.7e+00
1.0e+50
2.3e+00
1.3e+00
9.4e-01
cases:31.78%
controls:20.03%
cases:21.43%
controls:5.76%
cases:10.25%
controls:0.78%
cases:11.49%
controls:0.00%
cases:3.75%
controls:0.41%
cases:16.50%
controls:5.08%
cases:34.56%
controls:17.03%
102
639
219
2551
69
184
253
3012
33
25
289
3171
37
0
285
3196
12
13
308
3176
51
159
258
2968
94
472
178
2299
olanzapine; oral, parenteral
N05AH03 [21604543]
1.8e+00
2.6e+00
—
—
—
2.7e+00
2.2e+00
cases:4.36%
controls:0.75%
cases:4.97%
controls:0.38%
—
—
—
—
—
—
cases:4.85%
controls:0.35%
cases:6.25%
controls:0.76%
14
24
307
3166
16
12
306
3184
—
—
—
15
11
294
3116
17
21
255
2750
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
1.2e+00
1.5e+00
1.3e+00
—
1.5e+00
1.8e+00
1.7e+00
cases:21.50%
controls:7.34%
cases:25.78%
controls:7.35%
cases:8.39%
controls:2.38%
—
—
cases:10.00%
controls:2.32%
cases:34.30%
controls:7.74%
cases:36.76%
controls:9.20%
69
234
252
2956
83
235
239
2961
27
76
295
3120
—
32
74
288
3115
106
242
203
2885
100
255
172
2516
Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]
1.7e+00
2.8e+00
1.0e+50
—
1.0e+50
2.5e+00
2.1e+00
cases:4.36%
controls:0.85%
cases:5.59%
controls:0.34%
cases:2.80%
controls:0.00%
—
—
cases:2.19%
controls:0.00%
cases:4.53%
controls:0.38%
cases:10.29%
controls:1.41%
14
27
307
3163
18
11
304
3185
9
0
313
3196
—
7
0
313
3189
14
12
295
3115
28
39
244
2732
Inpatient Hospital
21 [8717]
7.6e-01
1.3e+00
2.4e+00
1.0e+50
2.5e+00
1.3e+00
9.3e-01
cases:43.93%
controls:26.90%
cases:25.78%
controls:8.67%
cases:11.49%
controls:1.16%
cases:21.74%
controls:0.00%
cases:8.13%
controls:0.75%
cases:23.95%
controls:8.19%
cases:43.38%
controls:23.24%
141
858
180
2332
83
277
239
2919
37
37
285
3159
70
0
252
3196
26
24
294
3165
74
256
235
2871
118
644
154
2127
Visual field defects
H53.4 [45557469]
2.9e+00
—
—
—
—
3.3e+00
2.9e+00
cases:2.80%
controls:0.16%
—
—
—
—
—
—
—
—
cases:4.21%
controls:0.16%
cases:4.78%
controls:0.29%
9
5
312
3185
—
—
—
—
13
5
296
3122
13
8
259
2763
lithium; oral
N05AN01 [21604556]
3.6e+00
2.9e+00
—
—
—
2.3e+00
—
cases:7.48%
controls:0.22%
cases:4.35%
controls:0.25%
—
—
—
—
—
—
cases:1.62%
controls:0.16%
—
—
24
7
297
3183
14
8
308
3188
—
—
—
5
5
304
3122
—
General Practice
1 [38004446]
6.5e-01
1.3e+00
2.4e+00
1.0e+50
2.1e+00
1.4e+00
9.5e-01
cases:15.26%
controls:8.59%
cases:10.87%
controls:3.16%
cases:5.59%
controls:0.53%
cases:2.80%
controls:0.00%
cases:3.13%
controls:0.38%
cases:11.00%
controls:3.10%
cases:21.32%
controls:9.49%
49
274
272
2916
35
101
287
3095
18
17
304
3179
9
0
313
3196
10
12
310
3177
34
97
275
3030
58
263
214
2508
Follitropin [Units/volume] in Serum or Plasma
15067-2 [3023323]
1.8e+00
2.6e+00
1.0e+50
—
—
2.3e+00
2.0e+00
cases:3.74%
controls:0.63%
cases:4.04%
controls:0.31%
cases:1.55%
controls:0.00%
—
—
—
—
cases:2.91%
controls:0.29%
cases:7.72%
controls:1.15%
12
20
309
3170
13
10
309
3186
5
0
317
3196
—
—
9
9
300
3118
21
32
251
2739
Ophthalmology
18 [38004463]
9.4e-01
1.6e+00
1.8e+00
1.0e+50
1.7e+00
1.4e+00
1.0e+00
cases:23.99%
controls:10.94%
cases:18.32%
controls:4.38%
cases:4.35%
controls:0.72%
cases:1.55%
controls:0.00%
cases:4.69%
controls:0.85%
cases:18.45%
controls:5.05%
cases:30.51%
controls:13.61%
77
349
244
2841
59
140
263
3056
14
23
308
3173
5
0
317
3196
15
27
305
3162
57
158
252
2969
83
377
189
2394
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.6e-01
7.0e-01
2.1e+00
3.3e+00
1.7e+00
7.7e-01
4.1e-01
cases:29.60%
controls:24.45%
cases:31.99%
controls:18.96%
cases:25.78%
controls:4.10%
cases:7.14%
controls:0.28%
cases:18.13%
controls:3.92%
cases:35.60%
controls:20.34%
cases:46.32%
controls:36.45%
95
780
226
2410
103
606
219
2590
83
131
239
3065
23
9
299
3187
58
125
262
3064
110
636
199
2491
126
1010
146
1761
Lutropin [Units/volume] in Serum or Plasma
10501-5 [3009214]
2.3e+00
3.3e+00
1.0e+50
—
—
—
2.8e+00
cases:3.12%
controls:0.31%
cases:4.97%
controls:0.19%
cases:2.48%
controls:0.00%
—
—
—
—
—
—
cases:8.09%
controls:0.51%
10
10
311
3180
16
6
306
3190
8
0
314
3196
—
—
—
22
14
250
2757
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.2e-01
5.7e-01
1.9e+00
3.1e+00
1.5e+00
6.2e-01
6.1e-01
cases:19.31%
controls:16.11%
cases:20.81%
controls:12.92%
cases:15.84%
controls:2.72%
cases:4.04%
controls:0.19%
cases:11.56%
controls:2.79%
cases:22.98%
controls:13.85%
cases:38.60%
controls:25.55%
62
514
259
2676
67
413
255
2783
51
87
271
3109
13
6
309
3190
37
89
283
3100
71
433
238
2694
105
708
167
2063
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
4.6e-01
1.1e+00
2.6e+00
—
1.9e+00
1.4e+00
9.9e-01
cases:20.56%
controls:14.08%
cases:21.12%
controls:8.23%
cases:14.29%
controls:1.19%
—
—
cases:6.25%
controls:0.97%
cases:25.89%
controls:7.87%
cases:41.18%
controls:20.57%
66
449
255
2741
68
263
254
2933
46
38
276
3158
—
20
31
300
3158
80
246
229
2881
112
570
160
2201
Emergency Room Visit
ER [9203]
7.1e-01
1.2e+00
1.8e+00
—
1.9e+00
1.1e+00
1.0e+00
cases:43.30%
controls:27.30%
cases:25.78%
controls:9.76%
cases:8.07%
controls:1.41%
—
—
cases:6.56%
controls:1.00%
cases:23.30%
controls:9.11%
cases:48.90%
controls:25.30%
139
871
182
2319
83
312
239
2884
26
45
296
3151
—
21
32
299
3157
72
285
237
2842
133
701
139
2070
levomepromazine; oral, parenteral
N05AA02 [21604493]
1.7e+00
2.5e+00
—
—
—
2.7e+00
2.3e+00
cases:2.18%
controls:0.41%
cases:1.86%
controls:0.16%
—
—
—
—
—
—
cases:2.27%
controls:0.16%
cases:2.94%
controls:0.29%
7
13
314
3177
6
5
316
3191
—
—
—
7
5
302
3122
8
8
264
2763
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
3.5e-01
7.7e-01
1.4e+00
3.2e+00
1.6e+00
5.4e-01
2.5e-01
cases:26.17%
controls:19.94%
cases:25.16%
controls:13.45%
cases:9.01%
controls:2.47%
cases:5.28%
controls:0.22%
cases:12.19%
controls:2.73%
cases:22.01%
controls:14.07%
cases:35.29%
controls:29.92%
84
636
237
2554
81
430
241
2766
29
79
293
3117
17
7
305
3189
39
87
281
3102
68
440
241
2687
96
829
176
1942
CBC panel - Blood by Automated count
58410-2 [40761511]
2.3e-01
6.3e-01
1.9e+00
3.0e+00
1.3e+00
6.9e-01
3.8e-01
cases:26.79%
controls:22.51%
cases:25.47%
controls:15.39%
cases:13.98%
controls:2.35%
cases:4.04%
controls:0.22%
cases:8.75%
controls:2.54%
cases:27.51%
controls:15.93%
cases:41.91%
controls:33.06%
86
718
235
2472
82
492
240
2704
45
75
277
3121
13
7
309
3189
28
81
292
3108
85
498
224
2629
114
916
158
1855
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
1.4e+00
1.8e+00
—
—
1.7e+00
2.1e+00
2.2e+00
cases:3.43%
controls:0.85%
cases:3.73%
controls:0.66%
—
—
—
—
cases:1.56%
controls:0.28%
cases:4.85%
controls:0.61%
cases:6.25%
controls:0.76%
11
27
310
3163
12
21
310
3175
—
—
5
9
315
3180
15
19
294
3108
17
21
255
2750
Headache
R51.80 [2000503603]
1.4e+00
2.0e+00
—
—
—
2.6e+00
1.5e+00
cases:5.92%
controls:1.60%
cases:4.66%
controls:0.63%
—
—
—
—
—
—
cases:3.24%
controls:0.26%
cases:7.72%
controls:1.91%
19
51
302
3139
15
20
307
3176
—
—
—
10
8
299
3119
21
53
251
2718
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.4e+00
1.9e+00
2.7e+00
—
—
1.3e+00
1.4e+00
cases:5.92%
controls:1.60%
cases:3.73%
controls:0.59%
cases:2.17%
controls:0.16%
—
—
—
—
cases:3.56%
controls:1.02%
cases:7.35%
controls:1.88%
19
51
302
3139
12
19
310
3177
7
5
315
3191
—
—
11
32
298
3095
20
52
252
2719
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
5.8e-01
1.0e+00
2.5e+00
—
1.5e+00
8.9e-01
6.8e-01
cases:14.33%
controls:8.56%
cases:10.56%
controls:4.01%
cases:7.14%
controls:0.63%
—
—
cases:3.44%
controls:0.78%
cases:8.74%
controls:3.77%
cases:22.06%
controls:12.49%
46
273
275
2917
34
128
288
3068
23
20
299
3176
—
11
25
309
3164
27
118
282
3009
60
346
212
2425
Pharmacy visit
OMOP4822462 [581458]
2.6e-01
8.6e-01
1.1e+00
2.1e+00
1.6e+00
1.4e+00
8.9e-01
cases:88.47%
controls:85.58%
cases:88.20%
controls:76.03%
cases:64.60%
controls:37.11%
cases:14.60%
controls:2.00%
cases:74.69%
controls:36.56%
cases:92.56%
controls:76.21%
cases:96.32%
controls:91.52%
284
2730
37
460
284
2430
38
766
208
1186
114
2010
47
64
275
3132
239
1166
81
2023
286
2383
23
744
262
2536
10
235
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.9e-01
1.2e+00
2.0e+00
—
1.5e+00
1.1e+00
7.0e-01
cases:17.13%
controls:10.25%
cases:13.98%
controls:4.85%
cases:5.28%
controls:0.72%
—
—
cases:4.06%
controls:0.91%
cases:13.27%
controls:5.05%
cases:25.00%
controls:14.18%
55
327
266
2863
45
155
277
3041
17
23
305
3173
—
13
29
307
3160
41
158
268
2969
68
393
204
2378
androstanolone
G03BB02 [21602513]
3.4e+00
—
1.0e+50
—
—
—
3.7e+00
cases:5.92%
controls:0.22%
—
—
cases:2.17%
controls:0.00%
—
—
—
—
—
—
cases:10.66%
controls:0.29%
19
7
302
3183
—
7
0
315
3196
—
—
—
29
8
243
2763
androstanolone
A14AA01 [21600917]
3.4e+00
—
1.0e+50
—
—
—
3.7e+00
cases:5.92%
controls:0.22%
—
—
cases:2.17%
controls:0.00%
—
—
—
—
—
—
cases:10.66%
controls:0.29%
19
7
302
3183
—
7
0
315
3196
—
—
—
29
8
243
2763
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
4.9e-01
1.4e+00
2.2e+00
—
2.3e+00
5.0e-01
9.3e-01
cases:6.85%
controls:4.29%
cases:8.39%
controls:2.13%
cases:3.11%
controls:0.34%
—
—
cases:3.13%
controls:0.31%
cases:4.21%
controls:2.59%
cases:14.34%
controls:6.17%
22
137
299
3053
27
68
295
3128
10
11
312
3185
—
10
10
310
3179
13
81
296
3046
39
171
233
2600
Psychiatry
26 [38004469]
1.3e+00
1.4e+00
1.2e+00
—
1.4e+00
1.4e+00
1.5e+00
cases:15.89%
controls:4.98%
cases:8.70%
controls:2.41%
cases:3.11%
controls:1.00%
—
—
cases:4.06%
controls:1.03%
cases:10.36%
controls:2.69%
cases:20.59%
controls:5.70%
51
159
270
3031
28
77
294
3119
10
32
312
3164
—
13
33
307
3156
32
84
277
3043
56
158
216
2613
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.2e-01
5.9e-01
1.7e+00
2.9e+00
1.2e+00
5.3e-01
2.6e-01
cases:29.28%
controls:26.87%
cases:34.16%
controls:22.28%
cases:21.12%
controls:4.69%
cases:6.21%
controls:0.38%
cases:15.00%
controls:4.92%
cases:34.30%
controls:23.50%
cases:47.43%
controls:41.14%
94
857
227
2333
110
712
212
2484
68
150
254
3046
20
12
302
3184
48
157
272
3032
106
735
203
2392
129
1140
143
1631
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.3e-01
5.9e-01
1.7e+00
2.9e+00
1.2e+00
5.4e-01
2.6e-01
cases:29.60%
controls:26.87%
cases:34.16%
controls:22.28%
cases:21.12%
controls:4.72%
cases:6.21%
controls:0.38%
cases:15.00%
controls:4.92%
cases:34.30%
controls:23.41%
cases:47.43%
controls:41.14%
95
857
226
2333
110
712
212
2484
68
151
254
3045
20
12
302
3184
48
157
272
3032
106
732
203
2395
129
1140
143
1631
MCH [Entitic mass]
28539-5 [3035941]
1.2e-01
6.0e-01
1.7e+00
2.8e+00
1.2e+00
5.4e-01
2.6e-01
cases:29.28%
controls:26.80%
cases:34.16%
controls:22.18%
cases:21.12%
controls:4.66%
cases:5.90%
controls:0.38%
cases:15.00%
controls:4.92%
cases:34.30%
controls:23.38%
cases:47.43%
controls:41.10%
94
855
227
2335
110
709
212
2487
68
149
254
3047
19
12
303
3184
48
157
272
3032
106
731
203
2396
129
1139
143
1632
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.2e-01
6.0e-01
1.7e+00
2.8e+00
1.2e+00
5.3e-01
2.6e-01
cases:29.28%
controls:26.87%
cases:34.16%
controls:22.25%
cases:21.12%
controls:4.69%
cases:5.90%
controls:0.38%
cases:15.00%
controls:4.92%
cases:34.30%
controls:23.44%
cases:47.43%
controls:41.14%
94
857
227
2333
110
711
212
2485
68
150
254
3046
19
12
303
3184
48
157
272
3032
106
733
203
2394
129
1140
143
1631
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.2e-01
6.0e-01
1.7e+00
2.8e+00
1.2e+00
5.3e-01
2.6e-01
cases:29.28%
controls:26.87%
cases:34.16%
controls:22.25%
cases:21.12%
controls:4.69%
cases:5.90%
controls:0.38%
cases:15.00%
controls:4.92%
cases:34.30%
controls:23.44%
cases:47.43%
controls:41.10%
94
857
227
2333
110
711
212
2485
68
150
254
3046
19
12
303
3184
48
157
272
3032
106
733
203
2394
129
1139
143
1632
Platelets [#/volume] in Blood
26515-7 [3007461]
1.2e-01
5.8e-01
1.7e+00
2.8e+00
1.2e+00
5.4e-01
2.6e-01
cases:29.28%
controls:26.77%
cases:33.85%
controls:22.22%
cases:21.12%
controls:4.69%
cases:5.90%
controls:0.38%
cases:15.00%
controls:4.92%
cases:34.30%
controls:23.35%
cases:47.43%
controls:41.03%
94
854
227
2336
109
710
213
2486
68
150
254
3046
19
12
303
3184
48
157
272
3032
106
730
203
2397
129
1137
143
1634
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.2e-01
5.9e-01
1.7e+00
2.8e+00
1.2e+00
5.3e-01
2.7e-01
cases:29.28%
controls:26.93%
cases:34.16%
controls:22.28%
cases:21.12%
controls:4.72%
cases:5.90%
controls:0.38%
cases:15.00%
controls:4.95%
cases:34.30%
controls:23.50%
cases:47.79%
controls:41.07%
94
859
227
2331
110
712
212
2484
68
151
254
3045
19
12
303
3184
48
158
272
3031
106
735
203
2392
130
1138
142
1633
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
5.8e-01
1.4e+00
2.2e+00
—
2.2e+00
6.6e-01
1.1e+00
cases:5.30%
controls:3.04%
cases:6.21%
controls:1.60%
cases:2.48%
controls:0.28%
—
—
cases:1.88%
controls:0.22%
cases:3.24%
controls:1.69%
cases:11.03%
controls:4.15%
17
97
304
3093
20
51
302
3145
8
9
314
3187
—
6
7
314
3182
10
53
299
3074
30
115
242
2656
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
5.8e-01
1.5e+00
2.2e+00
—
2.1e+00
4.9e-01
8.7e-01
cases:6.23%
controls:3.57%
cases:7.76%
controls:1.91%
cases:2.48%
controls:0.28%
—
—
cases:2.50%
controls:0.31%
cases:3.24%
controls:2.01%
cases:12.13%
controls:5.45%
20
114
301
3076
25
61
297
3135
8
9
314
3187
—
8
10
312
3179
10
63
299
3064
33
151
239
2620
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
1.7e+00
2.3e+00
—
—
—
2.0e+00
2.2e+00
cases:1.87%
controls:0.34%
cases:1.86%
controls:0.19%
—
—
—
—
—
—
cases:1.94%
controls:0.26%
cases:3.68%
controls:0.43%
6
11
315
3179
6
6
316
3190
—
—
—
6
8
303
3119
10
12
262
2759
More than one and less than three hours
ZXE10 [2001311401]
8.3e-01
1.7e+00
2.0e+00
—
—
2.0e+00
5.9e-01
cases:8.10%
controls:3.70%
cases:4.97%
controls:0.97%
cases:1.86%
controls:0.25%
—
—
—
—
cases:3.56%
controls:0.51%
cases:6.62%
controls:3.79%
26
118
295
3072
16
31
306
3165
6
8
316
3188
—
—
11
16
298
3111
18
105
254
2666
potassium chloride; oral
A12BA01 [21600877]
1.2e+00
1.8e+00
1.8e+00
—
—
2.7e+00
1.9e+00
cases:3.43%
controls:1.07%
cases:3.11%
controls:0.53%
cases:1.55%
controls:0.25%
—
—
—
—
cases:6.80%
controls:0.48%
cases:8.09%
controls:1.30%
11
34
310
3156
10
17
312
3179
5
8
317
3188
—
—
21
15
288
3112
22
36
250
2735
quetiapine; oral
N05AH04 [21604544]
9.4e-01
1.3e+00
1.8e+00
—
1.5e+00
1.2e+00
1.1e+00
cases:7.17%
controls:2.92%
cases:5.90%
controls:1.63%
cases:2.48%
controls:0.41%
—
—
cases:2.50%
controls:0.56%
cases:5.18%
controls:1.66%
cases:8.09%
controls:2.78%
23
93
298
3097
19
52
303
3144
8
13
314
3183
—
8
18
312
3171
16
52
293
3075
22
77
250
2694
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.4e-01
4.5e-01
1.7e+00
2.9e+00
1.3e+00
4.0e-01
4.7e-01
cases:19.63%
controls:16.08%
cases:19.57%
controls:13.45%
cases:13.66%
controls:2.82%
cases:3.73%
controls:0.22%
cases:9.38%
controls:2.79%
cases:19.42%
controls:13.91%
cases:35.29%
controls:25.41%
63
513
258
2677
63
430
259
2766
44
90
278
3106
12
7
310
3189
30
89
290
3100
60
435
249
2692
96
704
176
2067
Leukocytes [#/volume] in Urine
30405-5 [3018095]
6.5e-01
1.4e+00
2.1e+00
—
2.0e+00
5.4e-01
7.2e-01
cases:7.48%
controls:4.04%
cases:8.39%
controls:2.22%
cases:2.80%
controls:0.34%
—
—
cases:2.81%
controls:0.38%
cases:4.21%
controls:2.49%
cases:12.87%
controls:6.68%
24
129
297
3061
27
71
295
3125
9
11
313
3185
—
9
12
311
3177
13
78
296
3049
35
185
237
2586
Bacteria identified in Blood by Culture
600-7 [3023368]
9.3e-01
1.7e+00
2.7e+00
—
—
1.0e+00
9.4e-01
cases:5.61%
controls:2.29%
cases:4.66%
controls:0.88%
cases:2.17%
controls:0.16%
—
—
—
—
cases:3.56%
controls:1.34%
cases:9.56%
controls:3.97%
18
73
303
3117
15
28
307
3168
7
5
315
3191
—
—
11
42
298
3085
26
110
246
2661
Pediatric Endocrinology
OMOP4822030 [45756809]
1.8e+00
1.8e+00
—
—
—
2.2e+00
2.2e+00
cases:2.18%
controls:0.38%
cases:1.55%
controls:0.25%
—
—
—
—
—
—
cases:1.94%
controls:0.22%
cases:2.94%
controls:0.32%
7
12
314
3178
5
8
317
3188
—
—
—
6
7
303
3120
8
9
264
2762
macrogol; oral
A06AD15 [21600575]
7.0e-01
2.0e+00
—
—
—
2.5e+00
1.6e+00
cases:2.18%
controls:1.10%
cases:2.17%
controls:0.31%
—
—
—
—
—
—
cases:3.56%
controls:0.29%
cases:4.78%
controls:0.97%
7
35
314
3155
7
10
315
3186
—
—
—
11
9
298
3118
13
27
259
2744
Prolactin [Units/volume] in Serum or Plasma
15081-3 [3021387]
2.4e+00
—
1.0e+50
—
—
—
3.6e+00
cases:6.85%
controls:0.66%
—
—
cases:7.45%
controls:0.00%
—
—
—
—
—
—
cases:18.01%
controls:0.58%
22
21
299
3169
—
24
0
298
3196
—
—
—
49
16
223
2755
Laboratory Visit
OMOP4822461 [32036]
9.5e-02
3.4e-01
1.6e+00
2.8e+00
1.1e+00
4.8e-01
1.3e-01
cases:33.33%
controls:31.25%
cases:36.65%
controls:29.07%
cases:30.43%
controls:8.42%
cases:9.01%
controls:0.59%
cases:24.06%
controls:9.31%
cases:41.10%
controls:30.22%
cases:49.26%
controls:45.98%
107
997
214
2193
118
929
204
2267
98
269
224
2927
29
19
293
3177
77
297
243
2892
127
945
182
2182
134
1274
138
1497
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
1.4e+00
1.9e+00
2.7e+00
1.0e+50
—
1.1e+00
5.3e-01
cases:4.67%
controls:1.16%
cases:3.42%
controls:0.53%
cases:2.17%
controls:0.16%
cases:2.17%
controls:0.00%
—
—
cases:2.27%
controls:0.74%
cases:3.68%
controls:2.20%
15
37
306
3153
11
17
311
3179
7
5
315
3191
7
0
315
3196
—
7
23
302
3104
10
61
262
2710
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
8.5e-01
8.3e-01
1.5e+00
—
2.0e+00
6.4e-01
7.6e-01
cases:14.02%
controls:6.52%
cases:7.76%
controls:3.54%
cases:3.42%
controls:0.75%
—
—
cases:5.00%
controls:0.72%
cases:7.44%
controls:4.06%
cases:19.49%
controls:10.18%
45
208
276
2982
25
113
297
3083
11
24
311
3172
—
16
23
304
3166
23
127
286
3000
53
282
219
2489
oxazepam; oral
N05BA04 [21604569]
8.4e-01
1.3e+00
1.4e+00
—
1.7e+00
1.0e+00
1.0e+00
cases:8.41%
controls:3.82%
cases:7.76%
controls:2.25%
cases:2.48%
controls:0.63%
—
—
cases:3.13%
controls:0.56%
cases:6.80%
controls:2.53%
cases:11.76%
controls:4.62%
27
122
294
3068
25
72
297
3124
8
20
314
3176
—
10
18
310
3171
21
79
288
3048
32
128
240
2643
Microorganisms panel - Urine sediment
58435-9 [40761536]
1.2e+00
2.1e+00
—
—
—
1.9e+00
1.9e+00
cases:3.43%
controls:1.03%
cases:2.80%
controls:0.34%
—
—
—
—
—
—
cases:2.91%
controls:0.45%
cases:6.25%
controls:1.01%
11
33
310
3157
9
11
313
3185
—
—
—
9
14
300
3113
17
28
255
2743
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.1e+00
1.8e+00
—
—
—
1.6e+00
1.2e+00
cases:4.67%
controls:1.66%
cases:4.04%
controls:0.66%
—
—
—
—
—
—
cases:3.56%
controls:0.70%
cases:6.99%
controls:2.20%
15
53
306
3137
13
21
309
3175
—
—
—
11
22
298
3105
19
61
253
2710
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3.0e-01
9.2e-01
1.9e+00
—
1.5e+00
9.0e-01
5.4e-01
cases:23.36%
controls:18.43%
cases:24.53%
controls:11.42%
cases:9.94%
controls:1.69%
—
—
cases:5.94%
controls:1.35%
cases:23.62%
controls:11.16%
cases:39.34%
controls:27.43%
75
588
246
2602
79
365
243
2831
32
54
290
3142
—
19
43
301
3146
73
349
236
2778
107
760
165
2011
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
6.9e-01
1.0e+00
2.5e+00
—
2.3e+00
9.5e-01
9.7e-01
cases:6.54%
controls:3.39%
cases:4.04%
controls:1.50%
cases:2.17%
controls:0.19%
—
—
cases:2.19%
controls:0.22%
cases:3.88%
controls:1.54%
cases:13.24%
controls:5.49%
21
108
300
3082
13
48
309
3148
7
6
315
3190
—
7
7
313
3182
12
48
297
3079
36
152
236
2619
Case Management Agency
251B00000X [38004193]
3.8e-01
3.8e-01
8.5e-01
2.9e+00
1.2e+00
7.3e-01
3.4e-01
cases:61.68%
controls:52.48%
cases:54.66%
controls:45.12%
cases:31.99%
controls:16.74%
cases:21.43%
controls:1.44%
cases:42.50%
controls:18.09%
cases:63.43%
controls:45.44%
cases:70.22%
controls:62.68%
198
1674
123
1516
176
1442
146
1754
103
535
219
2661
69
46
253
3150
136
577
184
2612
196
1421
113
1706
191
1737
81
1034
Otolaryngology
4 [38004449]
7.6e-01
1.3e+00
—
—
1.9e+00
1.2e+00
5.9e-01
cases:18.38%
controls:9.56%
cases:11.18%
controls:3.41%
—
—
—
—
cases:3.13%
controls:0.47%
cases:9.06%
controls:2.97%
cases:16.91%
controls:10.14%
59
305
262
2885
36
109
286
3087
—
—
10
15
310
3174
28
93
281
3034
46
281
226
2490
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
4.9e-01
1.1e+00
1.9e+00
—
1.4e+00
7.3e-01
5.8e-01
cases:16.82%
controls:11.07%
cases:14.60%
controls:5.57%
cases:4.97%
controls:0.78%
—
—
cases:3.75%
controls:0.97%
cases:11.65%
controls:5.98%
cases:25.00%
controls:15.70%
54
353
267
2837
47
178
275
3018
16
25
306
3171
—
12
31
308
3158
36
187
273
2940
68
435
204
2336
Supplier / Service Provider
OMOP5117446 [33004]
-1.0e+00
-2.8e-01
—
—
—
3.5e+00
3.1e+00
cases:11.84%
controls:26.90%
cases:6.21%
controls:8.07%
—
—
—
—
—
—
cases:5.18%
controls:0.16%
cases:20.96%
controls:1.19%
38
858
283
2332
20
258
302
2938
—
—
—
16
5
293
3122
57
33
215
2738
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
7.4e-01
9.7e-01
1.6e+00
—
1.5e+00
5.9e-01
7.9e-01
cases:14.95%
controls:7.71%
cases:12.73%
controls:5.23%
cases:4.66%
controls:1.00%
—
—
cases:5.63%
controls:1.32%
cases:9.39%
controls:5.40%
cases:22.43%
controls:11.55%
48
246
273
2944
41
167
281
3029
15
32
307
3164
—
18
42
302
3147
29
169
280
2958
61
320
211
2451
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.5e-04
3.8e-01
1.4e+00
3.1e+00
1.1e+00
1.8e-01
1.0e-01
cases:19.63%
controls:19.62%
cases:21.12%
controls:15.46%
cases:11.49%
controls:3.13%
cases:4.04%
controls:0.19%
cases:9.06%
controls:3.36%
cases:19.09%
controls:16.44%
cases:33.09%
controls:30.82%
63
626
258
2564
68
494
254
2702
37
100
285
3096
13
6
309
3190
29
107
291
3082
59
514
250
2613
90
854
182
1917
Nephrology
39 [38004479]
1.1e+00
1.6e+00
—
—
—
2.0e+00
2.0e+00
cases:1.87%
controls:0.63%
cases:2.48%
controls:0.50%
—
—
—
—
—
—
cases:2.91%
controls:0.42%
cases:4.41%
controls:0.65%
6
20
315
3170
8
16
314
3180
—
—
—
9
13
300
3114
12
18
260
2753
Eosinophils [#/volume] in Blood
26449-9 [3013115]
6.6e-01
8.9e-01
1.5e+00
—
1.7e+00
5.4e-01
7.6e-01
cases:12.77%
controls:7.05%
cases:9.94%
controls:4.32%
cases:3.11%
controls:0.72%
—
—
cases:5.00%
controls:0.94%
cases:8.09%
controls:4.86%
cases:20.59%
controls:10.79%
41
225
280
2965
32
138
290
3058
10
23
312
3173
—
16
30
304
3159
25
152
284
2975
56
299
216
2472
Differential panel, method unspecified - Blood
69738-3 [42870588]
8.1e-01
1.3e+00
1.3e+00
—
2.3e+00
7.8e-01
1.0e+00
cases:8.72%
controls:4.08%
cases:8.39%
controls:2.35%
cases:1.86%
controls:0.53%
—
—
cases:3.75%
controls:0.38%
cases:6.15%
controls:2.91%
cases:15.07%
controls:6.03%
28
130
293
3060
27
75
295
3121
6
17
316
3179
—
12
12
308
3177
19
91
290
3036
41
167
231
2604
Examination of eyes and vision
Z01.0 [45566391]
1.6e+00
2.3e+00
—
—
—
1.5e+00
7.4e-01
cases:9.03%
controls:1.94%
cases:5.90%
controls:0.59%
—
—
—
—
—
—
cases:3.56%
controls:0.80%
cases:5.88%
controls:2.89%
29
62
292
3128
19
19
303
3177
—
—
—
11
25
298
3102
16
80
256
2691
Thorax X-ray examination
GD1AA [2001303617]
4.8e-01
1.0e+00
2.0e+00
1.0e+50
-1.0e+50
1.6e+00
8.6e-01
cases:9.35%
controls:6.02%
cases:4.97%
controls:1.88%
cases:2.17%
controls:0.31%
cases:3.42%
controls:0.00%
cases:0.00%
controls:0.19%
cases:7.12%
controls:1.50%
cases:14.34%
controls:6.60%
30
192
291
2998
16
60
306
3136
7
10
315
3186
11
0
311
3196
0
6
320
3183
22
47
287
3080
39
183
233
2588
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
1.8e+00
1.9e+00
—
—
—
1.2e+00
1.8e+00
cases:4.67%
controls:0.82%
cases:3.11%
controls:0.50%
—
—
—
—
—
—
cases:1.94%
controls:0.58%
cases:6.99%
controls:1.23%
15
26
306
3164
10
16
312
3180
—
—
—
6
18
303
3109
19
34
253
2737
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
4.8e-01
6.6e-01
1.7e+00
—
1.7e+00
7.3e-01
6.5e-01
cases:19.00%
controls:12.66%
cases:13.66%
controls:7.57%
cases:6.21%
controls:1.25%
—
—
cases:6.56%
controls:1.32%
cases:16.18%
controls:8.51%
cases:29.78%
controls:18.08%
61
404
260
2786
44
242
278
2954
20
40
302
3156
—
21
42
299
3147
50
266
259
2861
81
501
191
2270
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
6.4e-01
1.3e+00
1.8e+00
—
1.2e+00
9.4e-01
6.4e-01
cases:11.53%
controls:6.46%
cases:10.56%
controls:3.13%
cases:3.42%
controls:0.56%
—
—
cases:2.50%
controls:0.78%
cases:9.71%
controls:4.03%
cases:20.59%
controls:11.98%
37
206
284
2984
34
100
288
3096
11
18
311
3178
—
8
25
312
3164
30
126
279
3001
56
332
216
2439
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
6.6e-01
1.3e+00
1.8e+00
—
1.2e+00
8.6e-01
6.3e-01
cases:12.15%
controls:6.65%
cases:10.87%
controls:3.16%
cases:3.42%
controls:0.59%
—
—
cases:2.50%
controls:0.78%
cases:9.39%
controls:4.19%
cases:20.59%
controls:12.09%
39
212
282
2978
35
101
287
3095
11
19
311
3177
—
8
25
312
3164
29
131
280
2996
56
335
216
2436
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
7.7e-01
1.7e+00
2.5e+00
—
2.3e+00
1.0e+00
1.1e+00
cases:4.67%
controls:2.23%
cases:4.97%
controls:0.97%
cases:1.86%
controls:0.16%
—
—
cases:1.56%
controls:0.16%
cases:2.91%
controls:1.09%
cases:8.09%
controls:2.96%
15
71
306
3119
16
31
306
3165
6
5
316
3191
—
5
5
315
3184
9
34
300
3093
22
82
250
2689
Valproate [Moles/volume] in Serum or Plasma
14946-8 [3009466]
—
—
—
—
—
2.5e+00
2.7e+00
—
—
—
—
—
—
—
—
—
—
cases:2.27%
controls:0.19%
cases:3.68%
controls:0.25%
—
—
—
—
—
7
6
302
3121
10
7
262
2764
Calcium [Moles/time] in 24 hour Urine
14637-3 [3010838]
—
—
—
—
—
2.3e+00
2.8e+00
—
—
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.16%
cases:2.94%
controls:0.18%
—
—
—
—
—
5
5
304
3122
8
5
264
2766
prednisolone; oral, parenteral
H02AB06 [21602734]
2.2e-01
9.5e-01
—
—
1.9e+00
1.3e+00
9.7e-01
cases:10.90%
controls:8.97%
cases:8.70%
controls:3.57%
—
—
—
—
cases:2.50%
controls:0.38%
cases:12.62%
controls:3.84%
cases:20.22%
controls:8.73%
35
286
286
2904
28
114
294
3082
—
—
8
12
312
3177
39
120
270
3007
55
242
217
2529
prednisolone
A07EA01 [21600653]
2.0e-01
9.3e-01
—
—
1.9e+00
1.3e+00
9.8e-01
cases:10.90%
controls:9.09%
cases:8.70%
controls:3.63%
—
—
—
—
cases:2.50%
controls:0.38%
cases:12.62%
controls:3.84%
cases:20.59%
controls:8.84%
35
290
286
2900
28
116
294
3080
—
—
8
12
312
3177
39
120
270
3007
56
245
216
2526
Observation for other suspected diseases and conditions
Z03.80 [2000503756]
2.7e+00
—
—
—
—
—
2.3e+00
cases:3.74%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.22%
12
8
309
3182
—
—
—
—
—
6
6
266
2765
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
6.8e-01
1.2e+00
1.7e+00
—
1.4e+00
8.2e-01
6.4e-01
cases:9.97%
controls:5.30%
cases:10.25%
controls:3.22%
cases:3.42%
controls:0.66%
—
—
cases:3.13%
controls:0.75%
cases:6.80%
controls:3.10%
cases:12.87%
controls:7.25%
32
169
289
3021
33
103
289
3093
11
21
311
3175
—
10
24
310
3165
21
97
288
3030
35
201
237
2570
Home Visit
OMOP4822459 [581476]
9.9e-01
1.1e+00
1.5e+00
—
1.7e+00
1.2e+00
4.2e-01
cases:9.03%
controls:3.54%
cases:4.97%
controls:1.78%
cases:2.17%
controls:0.47%
—
—
cases:3.13%
controls:0.56%
cases:6.80%
controls:2.08%
cases:6.99%
controls:4.69%
29
113
292
3077
16
57
306
3139
7
15
315
3181
—
10
18
310
3171
21
65
288
3062
19
130
253
2641
Lysozyme [Mass/volume] in Serum or Plasma
2589-0 [3012110]
2.5e+00
—
—
—
—
—
2.5e+00
cases:1.87%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.25%
6
5
315
3185
—
—
—
—
—
8
7
264
2764
temazepam; oral
N05CD07 [21604642]
1.0e+00
1.1e+00
—
—
-1.0e+50
1.2e+00
1.5e+00
cases:6.54%
controls:2.41%
cases:4.97%
controls:1.66%
—
—
—
—
cases:0.00%
controls:0.31%
cases:4.85%
controls:1.57%
cases:11.40%
controls:2.67%
21
77
300
3113
16
53
306
3143
—
—
0
10
320
3179
15
49
294
3078
31
74
241
2697
lactulose; oral
A06AD11 [21600571]
1.3e+00
—
—
—
—
1.9e+00
1.6e+00
cases:3.74%
controls:1.03%
—
—
—
—
—
—
—
—
cases:3.56%
controls:0.54%
cases:6.25%
controls:1.26%
12
33
309
3157
—
—
—
—
11
17
298
3110
17
35
255
2736
Protein [Mass/volume] in Cerebral spinal fluid
2880-3 [3019473]
2.5e+00
—
—
—
—
—
2.3e+00
cases:1.87%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.32%
6
5
315
3185
—
—
—
—
—
9
9
263
2762
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
6.6e-01
1.3e+00
1.9e+00
—
8.3e-01
9.5e-01
6.5e-01
cases:10.28%
controls:5.61%
cases:9.01%
controls:2.53%
cases:2.48%
controls:0.38%
—
—
cases:1.56%
controls:0.69%
cases:7.77%
controls:3.17%
cases:16.18%
controls:9.17%
33
179
288
3011
29
81
293
3115
8
12
314
3184
—
5
22
315
3167
24
99
285
3028
44
254
228
2517
moxonidine; oral
C02AC05 [21600401]
2.2e+00
2.7e+00
—
—
—
—
1.8e+00
cases:2.18%
controls:0.25%
cases:2.17%
controls:0.16%
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.36%
7
8
314
3182
7
5
315
3191
—
—
—
—
6
10
266
2761
lamotrigine; oral
N03AX09 [21604431]
1.0e+00
—
—
—
—
2.3e+00
2.5e+00
cases:1.56%
controls:0.56%
—
—
—
—
—
—
—
—
cases:1.94%
controls:0.19%
cases:4.04%
controls:0.36%
5
18
316
3172
—
—
—
—
6
6
303
3121
11
10
261
2761
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
1.3e+00
1.7e+00
—
1.0e+50
—
1.8e+00
1.0e+00
cases:3.74%
controls:1.07%
cases:3.73%
controls:0.69%
—
—
cases:2.17%
controls:0.00%
—
—
cases:2.59%
controls:0.45%
cases:3.68%
controls:1.37%
12
34
309
3156
12
22
310
3174
—
7
0
315
3196
—
8
14
301
3113
10
38
262
2733
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
1.3e+00
1.7e+00
—
1.0e+50
—
1.8e+00
1.0e+00
cases:3.74%
controls:1.07%
cases:3.73%
controls:0.69%
—
—
cases:2.17%
controls:0.00%
—
—
cases:2.59%
controls:0.45%
cases:3.68%
controls:1.37%
12
34
309
3156
12
22
310
3174
—
7
0
315
3196
—
8
14
301
3113
10
38
262
2733
pH of Arterial blood
2744-1 [3019977]
1.3e+00
1.7e+00
—
1.0e+50
—
1.7e+00
9.3e-01
cases:4.05%
controls:1.10%
cases:3.73%
controls:0.69%
—
—
cases:2.17%
controls:0.00%
—
—
cases:2.59%
controls:0.48%
cases:3.68%
controls:1.48%
13
35
308
3155
12
22
310
3174
—
7
0
315
3196
—
8
15
301
3112
10
41
262
2730
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
6.2e-01
1.4e+00
1.8e+00
—
1.2e+00
8.6e-01
6.5e-01
cases:11.53%
controls:6.55%
cases:11.18%
controls:3.13%
cases:3.42%
controls:0.59%
—
—
cases:2.50%
controls:0.78%
cases:9.39%
controls:4.19%
cases:20.96%
controls:12.16%
37
209
284
2981
36
100
286
3096
11
19
311
3177
—
8
25
312
3164
29
131
280
2996
57
337
215
2434
Estradiol (E2) [Moles/volume] in Serum or Plasma
14715-7 [3026725]
2.3e+00
2.1e+00
—
—
—
—
2.3e+00
cases:1.87%
controls:0.19%
cases:1.55%
controls:0.19%
—
—
—
—
—
—
—
—
cases:4.78%
controls:0.51%
6
6
315
3184
5
6
317
3190
—
—
—
—
13
14
259
2757
Other specified urinary incontinence
N39.4 [45577525]
1.8e+00
2.8e+00
—
—
—
2.0e+00
8.8e-01
cases:3.74%
controls:0.66%
cases:4.04%
controls:0.25%
—
—
—
—
—
—
cases:1.62%
controls:0.22%
cases:2.57%
controls:1.08%
12
21
309
3169
13
8
309
3188
—
—
—
5
7
304
3120
7
30
265
2741
Bacteria [Presence] in Urine
87829-8 [36304419]
6.6e-01
1.4e+00
2.2e+00
—
1.9e+00
5.8e-01
1.0e+00
cases:5.30%
controls:2.82%
cases:5.90%
controls:1.56%
cases:2.48%
controls:0.28%
—
—
cases:1.88%
controls:0.28%
cases:2.59%
controls:1.47%
cases:11.03%
controls:4.37%
17
90
304
3100
19
50
303
3146
8
9
314
3187
—
6
9
314
3180
8
46
301
3081
30
121
242
2650
Emergency Medicine
93 [38004510]
4.8e-01
9.2e-01
1.9e+00
—
1.4e+00
1.0e+00
5.6e-01
cases:14.95%
controls:9.81%
cases:12.11%
controls:5.19%
cases:4.66%
controls:0.72%
—
—
cases:2.50%
controls:0.63%
cases:14.24%
controls:5.66%
cases:24.63%
controls:15.77%
48
313
273
2877
39
166
283
3030
15
23
307
3173
—
8
20
312
3169
44
177
265
2950
67
437
205
2334
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
8.7e-01
1.4e+00
1.7e+00
—
1.2e+00
1.1e+00
9.4e-01
cases:8.10%
controls:3.57%
cases:7.14%
controls:1.78%
cases:2.17%
controls:0.41%
—
—
cases:1.88%
controls:0.56%
cases:6.80%
controls:2.27%
cases:14.71%
controls:6.32%
26
114
295
3076
23
57
299
3139
7
13
315
3183
—
6
18
314
3171
21
71
288
3056
40
175
232
2596
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
1.2e+00
2.0e+00
—
—
—
1.3e+00
2.4e+00
cases:2.80%
controls:0.85%
cases:2.80%
controls:0.41%
—
—
—
—
—
—
cases:1.62%
controls:0.45%
cases:7.72%
controls:0.72%
9
27
312
3163
9
13
313
3183
—
—
—
5
14
304
3113
21
20
251
2751
Other obesity
E66.8 [45533036]
—
2.3e+00
—
—
—
2.5e+00
1.8e+00
—
—
cases:1.55%
controls:0.16%
—
—
—
—
—
—
cases:1.94%
controls:0.16%
cases:3.31%
controls:0.54%
—
5
5
317
3191
—
—
—
6
5
303
3122
9
15
263
2756
solifenacin; oral
G04BD08 [21602641]
1.2e+00
2.2e+00
—
—
—
2.2e+00
1.1e+00
cases:1.87%
controls:0.56%
cases:1.86%
controls:0.22%
—
—
—
—
—
—
cases:1.94%
controls:0.22%
cases:1.84%
controls:0.65%
6
18
315
3172
6
7
316
3189
—
—
—
6
7
303
3120
5
18
267
2753
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
—
—
—
—
—
2.3e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.16%
cases:3.31%
controls:0.51%
—
—
—
—
—
5
5
304
3122
9
14
263
2757
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
8.6e-01
1.6e+00
—
—
—
1.0e+00
7.4e-01
cases:8.10%
controls:3.61%
cases:6.83%
controls:1.44%
—
—
—
—
—
—
cases:5.18%
controls:1.95%
cases:11.03%
controls:5.59%
26
115
295
3075
22
46
300
3150
—
—
—
16
61
293
3066
30
155
242
2616
Essential (primary) hypertension
I10 [45591453]
2.5e-01
7.5e-01
1.7e+00
—
1.7e+00
5.2e-01
4.4e-01
cases:14.02%
controls:11.32%
cases:11.80%
controls:5.94%
cases:3.73%
controls:0.69%
—
—
cases:4.69%
controls:0.88%
cases:10.68%
controls:6.62%
cases:20.59%
controls:14.29%
45
361
276
2829
38
190
284
3006
12
22
310
3174
—
15
28
305
3161
33
207
276
2920
56
396
216
2375
zopiclone; oral
N05CF01 [21604654]
1.1e+00
1.3e+00
1.1e+00
—
1.1e+00
1.0e+00
7.4e-01
cases:13.71%
controls:5.20%
cases:9.63%
controls:2.91%
cases:2.17%
controls:0.72%
—
—
cases:2.50%
controls:0.85%
cases:8.41%
controls:3.13%
cases:12.13%
controls:6.17%
44
166
277
3024
31
93
291
3103
7
23
315
3173
—
8
27
312
3162
26
98
283
3029
33
171
239
2600
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
1.3e+00
2.2e+00
—
—
—
—
1.9e+00
cases:2.80%
controls:0.78%
cases:3.42%
controls:0.41%
—
—
—
—
—
—
—
—
cases:6.62%
controls:1.05%
9
25
312
3165
11
13
311
3183
—
—
—
—
18
29
254
2742
calcium (different salts in combination); oral
A12AA20 [21600872]
8.3e-01
9.6e-01
8.2e-01
—
1.3e+00
1.1e+00
1.1e+00
cases:11.21%
controls:5.24%
cases:9.94%
controls:4.04%
cases:2.17%
controls:0.97%
—
—
cases:3.13%
controls:0.91%
cases:12.62%
controls:4.41%
cases:18.38%
controls:6.93%
36
167
285
3023
32
129
290
3067
7
31
315
3165
—
10
29
310
3160
39
138
270
2989
50
192
222
2579
Physical Medicine And Rehabilitation
25 [38004468]
8.0e-01
1.0e+00
—
—
1.6e+00
1.1e+00
1.0e+00
cases:10.90%
controls:5.20%
cases:4.97%
controls:1.81%
—
—
—
—
cases:1.88%
controls:0.38%
cases:6.47%
controls:2.17%
cases:15.81%
controls:6.21%
35
166
286
3024
16
58
306
3138
—
—
6
12
314
3177
20
68
289
3059
43
172
229
2599
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
—
2.1e+00
—
—
-1.0e+50
1.5e+00
1.9e+00
—
—
cases:2.17%
controls:0.28%
—
—
—
—
cases:0.00%
controls:0.16%
cases:1.62%
controls:0.35%
cases:4.41%
controls:0.69%
—
7
9
315
3187
—
—
0
5
320
3184
5
11
304
3116
12
19
260
2752
Dizziness and giddiness
R42 [45568132]
1.2e+00
1.8e+00
—
—
—
—
9.9e-01
cases:6.54%
controls:2.10%
cases:3.42%
controls:0.59%
—
—
—
—
—
—
—
—
cases:6.99%
controls:2.71%
21
67
300
3123
11
19
311
3177
—
—
—
—
19
75
253
2696
Perimetry
XCK00 [2001301380]
2.1e+00
—
1.0e+50
—
—
—
1.9e+00
cases:4.05%
controls:0.53%
—
—
cases:1.86%
controls:0.00%
—
—
—
—
—
—
cases:4.04%
controls:0.65%
13
17
308
3173
—
6
0
316
3196
—
—
—
11
18
261
2753
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
4.3e-01
1.1e+00
1.8e+00
—
2.1e+00
6.7e-01
8.0e-01
cases:8.10%
controls:5.42%
cases:6.52%
controls:2.38%
cases:1.86%
controls:0.31%
—
—
cases:2.19%
controls:0.28%
cases:6.47%
controls:3.42%
cases:19.49%
controls:9.78%
26
173
295
3017
21
76
301
3120
6
10
316
3186
—
7
9
313
3180
20
107
289
3020
53
271
219
2500
Chronic kidney disease, unspecified
N18.9 [45553438]
2.1e+00
—
—
—
—
—
1.8e+00
cases:2.18%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:2.57%
controls:0.43%
7
9
314
3181
—
—
—
—
—
7
12
265
2759
Coloscopy
UJF32 [2001305029]
9.3e-01
1.4e+00
—
—
—
1.4e+00
1.5e+00
cases:5.92%
controls:2.41%
cases:2.17%
controls:0.53%
—
—
—
—
—
—
cases:3.56%
controls:0.86%
cases:9.19%
controls:2.24%
19
77
302
3113
7
17
315
3179
—
—
—
11
27
298
3100
25
62
247
2709
Gynecological ultrasound examination as part of clinical examination
LX1AE [2001306815]
1.3e+00
1.9e+00
—
—
—
2.5e+00
7.0e-01
cases:3.43%
controls:0.94%
cases:1.86%
controls:0.28%
—
—
—
—
—
—
cases:2.27%
controls:0.19%
cases:2.57%
controls:1.30%
11
30
310
3160
6
9
316
3187
—
—
—
7
6
302
3121
7
36
265
2735
Acute tubulo-interstitial nephritis
N10 [45543856]
1.4e+00
2.3e+00
—
—
—
1.8e+00
1.1e+00
cases:3.74%
controls:0.91%
cases:2.48%
controls:0.25%
—
—
—
—
—
—
cases:1.94%
controls:0.32%
cases:3.31%
controls:1.12%
12
29
309
3161
8
8
314
3188
—
—
—
6
10
303
3117
9
31
263
2740
Surface analgesia on skin or mucosa
WX105 [2001310765]
1.5e+00
2.2e+00
—
—
—
—
1.1e+00
cases:3.12%
controls:0.72%
cases:1.86%
controls:0.22%
—
—
—
—
—
—
—
—
cases:2.57%
controls:0.87%
10
23
311
3167
6
7
316
3189
—
—
—
—
7
24
265
2747
Insulin-like growth factor-I [Moles/volume] in Serum or Plasma
29775-4 [3014326]
3.6e+00
—
1.0e+50
—
1.0e+50
—
—
cases:5.61%
controls:0.16%
—
—
cases:4.35%
controls:0.00%
—
—
cases:3.13%
controls:0.00%
—
—
—
—
18
5
303
3185
—
14
0
308
3196
—
10
0
310
3189
—
—
Physiotherapy
R4110 [2001310233]
9.7e-01
1.5e+00
2.3e+00
—
—
6.2e-01
1.1e+00
cases:8.10%
controls:3.23%
cases:4.04%
controls:0.91%
cases:1.55%
controls:0.16%
—
—
—
—
cases:1.94%
controls:1.06%
cases:9.56%
controls:3.39%
26
103
295
3087
13
29
309
3167
5
5
317
3191
—
—
6
33
303
3094
26
94
246
2677
Bacteria identified in Urine by Culture
630-4 [3026008]
6.3e-01
7.6e-01
2.5e+00
—
1.7e+00
1.1e+00
7.0e-01
cases:6.85%
controls:3.76%
cases:3.73%
controls:1.78%
cases:2.17%
controls:0.19%
—
—
cases:1.56%
controls:0.28%
cases:4.53%
controls:1.54%
cases:11.03%
controls:5.77%
22
120
299
3070
12
57
310
3139
7
6
315
3190
—
5
9
315
3180
14
48
295
3079
30
160
242
2611
Basophils/Leukocytes in Blood
30180-4 [3022096]
5.8e-01
1.1e+00
1.2e+00
—
1.8e+00
4.0e-01
6.9e-01
cases:10.59%
controls:6.21%
cases:10.25%
controls:3.75%
cases:2.17%
controls:0.69%
—
—
cases:4.38%
controls:0.75%
cases:6.15%
controls:4.19%
cases:17.28%
controls:9.49%
34
198
287
2992
33
120
289
3076
7
22
315
3174
—
14
24
306
3165
19
131
290
2996
47
263
225
2508
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.1e-01
8.5e-01
6.1e-01
—
1.0e+00
9.0e-01
7.6e-01
cases:18.69%
controls:13.26%
cases:13.98%
controls:6.51%
cases:2.17%
controls:1.19%
—
—
cases:4.38%
controls:1.60%
cases:15.21%
controls:6.81%
cases:26.47%
controls:14.44%
60
423
261
2767
45
208
277
2988
7
38
315
3158
—
14
51
306
3138
47
213
262
2914
72
400
200
2371
Monocytes/Leukocytes in Blood
26485-3 [3019069]
5.5e-01
1.0e+00
1.2e+00
—
1.8e+00
4.0e-01
6.8e-01
cases:10.59%
controls:6.39%
cases:9.94%
controls:3.82%
cases:2.17%
controls:0.69%
—
—
cases:4.38%
controls:0.78%
cases:6.15%
controls:4.22%
cases:17.28%
controls:9.53%
34
204
287
2986
32
122
290
3074
7
22
315
3174
—
14
25
306
3164
19
132
290
2995
47
264
225
2507
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
5.0e-01
9.9e-01
1.1e+00
—
1.7e+00
3.1e-01
7.3e-01
cases:10.59%
controls:6.71%
cases:9.94%
controls:3.94%
cases:2.17%
controls:0.75%
—
—
cases:4.38%
controls:0.82%
cases:5.83%
controls:4.35%
cases:18.38%
controls:9.82%
34
214
287
2976
32
126
290
3070
7
24
315
3172
—
14
26
306
3163
18
136
291
2991
50
272
222
2499
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
5.7e-01
1.1e+00
1.2e+00
—
1.7e+00
4.1e-01
6.8e-01
cases:10.59%
controls:6.30%
cases:10.25%
controls:3.82%
cases:2.17%
controls:0.69%
—
—
cases:4.06%
controls:0.78%
cases:6.15%
controls:4.16%
cases:17.28%
controls:9.56%
34
201
287
2989
33
122
289
3074
7
22
315
3174
—
13
25
307
3164
19
130
290
2997
47
265
225
2506
Normoblasts [#/volume] in Blood
715-3 [3021589]
4.8e-01
8.0e-01
1.6e+00
—
1.1e+00
5.3e-01
9.5e-01
cases:8.41%
controls:5.36%
cases:9.32%
controls:4.41%
cases:5.28%
controls:1.06%
—
—
cases:3.44%
controls:1.16%
cases:8.09%
controls:4.92%
cases:19.85%
controls:8.73%
27
171
294
3019
30
141
292
3055
17
34
305
3162
—
11
37
309
3152
25
154
284
2973
54
242
218
2529
Monocytes [#/volume] in Blood
26484-6 [3001604]
6.1e-01
8.5e-01
1.3e+00
—
1.6e+00
5.1e-01
8.3e-01
cases:11.84%
controls:6.77%
cases:9.32%
controls:4.19%
cases:2.48%
controls:0.72%
—
—
cases:4.69%
controls:0.94%
cases:7.44%
controls:4.61%
cases:20.22%
controls:9.96%
38
216
283
2974
30
134
292
3062
8
23
314
3173
—
15
30
305
3159
23
144
286
2983
55
276
217
2495
Urology
34 [38004474]
8.3e-01
1.5e+00
—
—
—
1.0e+00
5.1e-01
cases:7.79%
controls:3.54%
cases:6.52%
controls:1.60%
—
—
—
—
—
—
cases:5.18%
controls:1.92%
cases:6.99%
controls:4.29%
25
113
296
3077
21
51
301
3145
—
—
—
16
60
293
3067
19
119
253
2652
Basophils [#/volume] in Blood
26444-0 [3006315]
6.2e-01
8.5e-01
1.3e+00
—
1.6e+00
5.0e-01
8.1e-01
cases:11.84%
controls:6.74%
cases:9.32%
controls:4.19%
cases:2.48%
controls:0.72%
—
—
cases:4.69%
controls:0.94%
cases:7.44%
controls:4.64%
cases:20.22%
controls:10.10%
38
215
283
2975
30
134
292
3062
8
23
314
3173
—
15
30
305
3159
23
145
286
2982
55
280
217
2491
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
1.4e+00
1.9e+00
2.1e+00
—
—
1.4e+00
1.0e+00
cases:4.36%
controls:1.13%
cases:3.73%
controls:0.56%
cases:1.55%
controls:0.19%
—
—
—
—
cases:2.91%
controls:0.77%
cases:3.68%
controls:1.34%
14
36
307
3154
12
18
310
3178
5
6
317
3190
—
—
9
24
300
3103
10
37
262
2734
Sleep apnoea
G47.3 [45562094]
4.3e-01
1.0e+00
1.7e+00
1.0e+50
—
1.2e+00
1.1e+00
cases:4.98%
controls:3.29%
cases:5.59%
controls:2.03%
cases:1.86%
controls:0.34%
cases:2.17%
controls:0.00%
—
—
cases:5.50%
controls:1.79%
cases:12.13%
controls:4.44%
16
105
305
3085
18
65
304
3131
6
11
316
3185
7
0
315
3196
—
17
56
292
3071
33
123
239
2648
Gastroenterology
10 [38004455]
1.0e+00
1.1e+00
—
—
—
7.8e-01
1.1e+00
cases:8.72%
controls:3.32%
cases:5.28%
controls:1.81%
—
—
—
—
—
—
cases:4.21%
controls:1.98%
cases:11.76%
controls:4.08%
28
106
293
3084
17
58
305
3138
—
—
—
13
62
296
3065
32
113
240
2658
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
6.0e-01
8.7e-01
1.2e+00
—
1.6e+00
4.8e-01
7.7e-01
cases:12.15%
controls:7.08%
cases:9.63%
controls:4.29%
cases:2.48%
controls:0.78%
—
—
cases:4.69%
controls:0.97%
cases:7.44%
controls:4.73%
cases:20.22%
controls:10.54%
39
226
282
2964
31
137
291
3059
8
25
314
3171
—
15
31
305
3158
23
148
286
2979
55
292
217
2479
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
1.4e+00
1.8e+00
—
1.0e+50
—
1.9e+00
9.5e-01
cases:3.43%
controls:0.85%
cases:2.80%
controls:0.47%
—
—
cases:1.86%
controls:0.00%
—
—
cases:1.94%
controls:0.29%
cases:3.31%
controls:1.30%
11
27
310
3163
9
15
313
3181
—
6
0
316
3196
—
6
9
303
3118
9
36
263
2735
Oxygen saturation in Arterial blood
2708-6 [3016502]
1.4e+00
1.9e+00
—
1.0e+50
—
1.6e+00
9.0e-01
cases:3.43%
controls:0.91%
cases:3.11%
controls:0.50%
—
—
cases:1.55%
controls:0.00%
—
—
cases:1.94%
controls:0.42%
cases:3.31%
controls:1.37%
11
29
310
3161
10
16
312
3180
—
5
0
317
3196
—
6
13
303
3114
9
38
263
2733
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
1.6e-01
8.9e-01
1.2e+00
—
2.1e+00
1.1e+00
6.2e-01
cases:5.61%
controls:4.80%
cases:5.59%
controls:2.38%
cases:1.86%
controls:0.56%
—
—
cases:2.81%
controls:0.34%
cases:5.83%
controls:2.11%
cases:12.87%
controls:7.33%
18
153
303
3037
18
76
304
3120
6
18
316
3178
—
9
11
311
3178
18
66
291
3061
35
203
237
2568
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
5.6e-01
9.0e-01
1.1e+00
—
1.6e+00
3.2e-01
6.1e-01
cases:10.59%
controls:6.36%
cases:9.32%
controls:4.01%
cases:2.17%
controls:0.75%
—
—
cases:4.06%
controls:0.82%
cases:5.83%
controls:4.29%
cases:16.54%
controls:9.71%
34
203
287
2987
30
128
292
3068
7
24
315
3172
—
13
26
307
3163
18
134
291
2993
45
269
227
2502
Physiotherapist
Z3226 [2001311560]
7.1e-01
1.9e+00
—
—
—
1.5e+00
1.2e+00
cases:3.74%
controls:1.88%
cases:2.48%
controls:0.38%
—
—
—
—
—
—
cases:2.27%
controls:0.51%
cases:4.78%
controls:1.44%
12
60
309
3130
8
12
314
3184
—
—
—
7
16
302
3111
13
40
259
2731
Base excess in Arterial blood by calculation
1925-7 [3003396]
1.4e+00
1.8e+00
—
1.0e+50
—
1.6e+00
9.3e-01
cases:4.05%
controls:1.07%
cases:3.73%
controls:0.66%
—
—
cases:1.86%
controls:0.00%
—
—
cases:2.27%
controls:0.48%
cases:3.68%
controls:1.48%
13
34
308
3156
12
21
310
3175
—
6
0
316
3196
—
7
15
302
3112
10
41
262
2730
Other and unspecified abdominal pain
R10.4 [45568113]
6.5e-01
1.2e+00
—
—
—
1.1e+00
8.9e-01
cases:7.17%
controls:3.86%
cases:4.04%
controls:1.31%
—
—
—
—
—
—
cases:4.21%
controls:1.47%
cases:8.82%
controls:3.83%
23
123
298
3067
13
42
309
3154
—
—
—
13
46
296
3081
24
106
248
2665
Pulmonary Disease
29 [38004472]
6.0e-01
9.8e-01
1.1e+00
—
—
1.1e+00
1.1e+00
cases:11.84%
controls:6.87%
cases:8.39%
controls:3.32%
cases:1.55%
controls:0.53%
—
—
—
—
cases:8.41%
controls:3.07%
cases:19.12%
controls:7.61%
38
219
283
2971
27
106
295
3090
5
17
317
3179
—
—
26
96
283
3031
52
211
220
2560
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
8.1e-01
1.5e+00
—
—
—
1.8e+00
1.5e+00
cases:3.74%
controls:1.69%
cases:2.80%
controls:0.63%
—
—
—
—
—
—
cases:1.94%
controls:0.32%
cases:5.88%
controls:1.37%
12
54
309
3136
9
20
313
3176
—
—
—
6
10
303
3117
16
38
256
2733
pH of Urine
2756-5 [3015736]
4.1e-01
1.2e+00
1.8e+00
—
1.2e+00
7.4e-01
3.2e-01
cases:8.10%
controls:5.52%
cases:7.45%
controls:2.32%
cases:2.48%
controls:0.44%
—
—
cases:1.88%
controls:0.60%
cases:6.15%
controls:3.04%
cases:13.24%
controls:9.96%
26
176
295
3014
24
74
298
3122
8
14
314
3182
—
6
19
314
3170
19
95
290
3032
36
276
236
2495
omeprazole; oral, parenteral
A02BC01 [21600096]
8.8e-01
1.1e+00
—
—
—
7.0e-01
9.8e-01
cases:8.10%
controls:3.54%
cases:4.04%
controls:1.41%
—
—
—
—
—
—
cases:3.24%
controls:1.63%
cases:8.82%
controls:3.50%
26
113
295
3077
13
45
309
3151
—
—
—
10
51
299
3076
24
97
248
2674
Obstetrics / Gynecology
16 [38004461]
4.4e-01
1.2e+00
5.4e-01
—
4.2e-01
1.1e+00
6.0e-01
cases:20.25%
controls:14.11%
cases:13.98%
controls:4.82%
cases:1.55%
controls:0.91%
—
—
cases:1.56%
controls:1.03%
cases:15.21%
controls:5.56%
cases:22.79%
controls:14.00%
65
450
256
2740
45
154
277
3042
5
29
317
3167
—
5
33
315
3156
47
174
262
2953
62
388
210
2383
Lumbar puncture
TAB00 [2001300538]
1.3e+00
—
—
—
—
—
2.8e+00
cases:1.87%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.18%
6
16
315
3174
—
—
—
—
—
8
5
264
2766
Bipolar affective disorder, unspecified
F31.9 [45571758]
2.7e+00
—
—
—
—
—
—
cases:2.80%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
9
6
312
3184
—
—
—
—
—
—
Infectious Disease
44 [38004484]
1.2e+00
1.5e+00
—
—
—
1.6e+00
1.5e+00
cases:4.36%
controls:1.35%
cases:2.17%
controls:0.47%
—
—
—
—
—
—
cases:1.94%
controls:0.42%
cases:5.51%
controls:1.26%
14
43
307
3147
7
15
315
3181
—
—
—
6
13
303
3114
15
35
257
2736
Macroprolactin [Units/volume] in Serum or Plasma
74953-1 [44816844]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.25%
—
—
—
—
—
—
10
7
262
2764
Prolactin monomeric [Units/volume] in Serum or Plasma
78994-1 [21491979]
—
1.0e+50
—
—
—
—
2.7e+00
—
—
cases:1.86%
controls:0.00%
—
—
—
—
—
—
—
—
cases:2.57%
controls:0.18%
—
6
0
316
3196
—
—
—
—
7
5
265
2766
Prolactin monomeric/Prolactin.total in Serum or Plasma
50366-4 [3031309]
—
1.0e+50
—
—
—
—
2.7e+00
—
—
cases:1.86%
controls:0.00%
—
—
—
—
—
—
—
—
cases:2.57%
controls:0.18%
—
6
0
316
3196
—
—
—
—
7
5
265
2766
Cell count panel - Cerebral spinal fluid
34563-7 [3044290]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.25%
—
—
—
—
—
—
9
7
263
2764
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
1.1e+00
1.3e+00
2.3e+00
—
—
1.3e+00
1.5e+00
cases:4.05%
controls:1.41%
cases:1.86%
controls:0.50%
cases:1.55%
controls:0.16%
—
—
—
—
cases:2.59%
controls:0.70%
cases:5.88%
controls:1.37%
13
45
308
3145
6
16
316
3180
5
5
317
3191
—
—
8
22
301
3105
16
38
256
2733
Leukocytes [#/volume] in Cerebral spinal fluid
26465-5 [3016543]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.29%
—
—
—
—
—
—
10
8
262
2763
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 [3027475]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.29%
—
—
—
—
—
—
10
8
262
2763
General Surgery
2 [38004447]
4.5e-01
9.2e-01
1.1e+00
1.0e+50
7.4e-01
9.8e-01
6.5e-01
cases:22.43%
controls:15.58%
cases:10.25%
controls:4.35%
cases:1.55%
controls:0.50%
cases:1.55%
controls:0.00%
cases:1.56%
controls:0.75%
cases:9.71%
controls:3.87%
cases:23.16%
controls:13.57%
72
497
249
2693
33
139
289
3057
5
16
317
3180
5
0
317
3196
5
24
315
3165
30
121
279
3006
63
376
209
2395
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
1.3e+00
1.1e+00
—
—
—
6.0e-01
1.2e+00
cases:3.74%
controls:1.00%
cases:1.55%
controls:0.53%
—
—
—
—
—
—
cases:1.62%
controls:0.90%
cases:6.25%
controls:1.98%
12
32
309
3158
5
17
317
3179
—
—
—
5
28
304
3099
17
55
255
2716
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
2.9e-01
7.2e-01
1.3e+00
—
—
1.8e-01
4.6e-01
cases:24.61%
controls:19.59%
cases:22.05%
controls:12.08%
cases:4.97%
controls:1.35%
—
—
—
—
cases:14.89%
controls:12.76%
cases:38.97%
controls:28.65%
79
625
242
2565
71
386
251
2810
16
43
306
3153
—
—
46
399
263
2728
106
794
166
1977
Bacteria identified in Cerebral spinal fluid by Culture
606-4 [3016914]
—
1.0e+50
—
—
—
—
2.5e+00
—
—
cases:1.86%
controls:0.00%
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.18%
—
6
0
316
3196
—
—
—
—
6
5
266
2766
Parathyrin.intact [Moles/volume] in Serum or Plasma
14866-8 [3010566]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.18%
—
—
—
—
—
—
6
5
266
2766
Visual field testing with Octopus automated perimetry
CS444 [2001301477]
1.7e+00
—
—
—
—
—
2.5e+00
cases:1.87%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.18%
6
11
315
3179
—
—
—
—
—
6
5
266
2766
Sodium [Moles/volume] in Urine
2955-3 [3003181]
—
—
—
—
1.0e+50
—
2.5e+00
—
—
—
—
—
—
—
—
cases:3.13%
controls:0.00%
—
—
cases:2.57%
controls:0.22%
—
—
—
—
10
0
310
3189
—
7
6
265
2765
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
1.1e+00
2.5e+00
—
—
—
8.4e-01
1.2e+00
cases:1.56%
controls:0.50%
cases:1.86%
controls:0.16%
—
—
—
—
—
—
cases:1.62%
controls:0.70%
cases:3.68%
controls:1.08%
5
16
316
3174
6
5
316
3191
—
—
—
5
22
304
3105
10
30
262
2741
Hematology
82 [38004501]
1.4e+00
1.6e+00
—
—
—
2.5e+00
1.3e+00
cases:2.18%
controls:0.56%
cases:2.17%
controls:0.44%
—
—
—
—
—
—
cases:2.27%
controls:0.19%
cases:2.94%
controls:0.83%
7
18
314
3172
7
14
315
3182
—
—
—
7
6
302
3121
8
23
264
2748
INR in Blood by Coagulation assay
34714-6 [3032080]
4.0e-01
9.3e-01
8.6e-01
—
1.1e+00
8.7e-01
6.8e-01
cases:8.72%
controls:6.02%
cases:8.39%
controls:3.47%
cases:2.48%
controls:1.06%
—
—
cases:3.13%
controls:1.07%
cases:7.44%
controls:3.26%
cases:16.54%
controls:9.13%
28
192
293
2998
27
111
295
3085
8
34
314
3162
—
10
34
310
3155
23
102
286
3025
45
253
227
2518
IgG subclass 4 [Mass/volume] in Serum
2469-5 [3024980]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.25%
—
—
—
—
—
—
8
7
264
2764
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
—
—
—
—
—
2.1e+00
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.19%
cases:2.94%
controls:0.25%
—
—
—
—
—
5
6
304
3121
8
7
264
2764
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
1.3e+00
1.2e+00
—
—
—
8.4e-01
1.2e+00
cases:4.05%
controls:1.19%
cases:1.86%
controls:0.59%
—
—
—
—
—
—
cases:2.27%
controls:0.99%
cases:6.99%
controls:2.17%
13
38
308
3152
6
19
316
3177
—
—
—
7
31
302
3096
19
60
253
2711
Dietary counselling and surveillance
Z71.3 [45552101]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.29%
—
—
—
—
—
—
9
8
263
2763
Retention of urine
R33 [45587507]
1.6e+00
—
—
—
—
—
2.5e+00
cases:1.87%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.32%
6
12
315
3178
—
—
—
—
—
10
9
262
2762
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
6.5e-01
1.3e+00
—
—
—
1.2e+00
7.8e-01
cases:6.54%
controls:3.54%
cases:4.66%
controls:1.35%
—
—
—
—
—
—
cases:4.21%
controls:1.34%
cases:7.72%
controls:3.68%
21
113
300
3077
15
43
307
3153
—
—
—
13
42
296
3085
21
102
251
2669
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
4.4e-01
1.4e+00
—
—
1.2e+00
9.9e-01
6.8e-01
cases:6.23%
controls:4.11%
cases:6.52%
controls:1.69%
—
—
—
—
cases:1.56%
controls:0.47%
cases:5.18%
controls:1.98%
cases:9.56%
controls:5.09%
20
131
301
3059
21
54
301
3142
—
—
5
15
315
3174
16
62
293
3065
26
141
246
2630
hydrocortisone
S01CB03 [21603666]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.22%
—
—
—
—
—
—
6
6
266
2765
hydrocortisone
S01BA02 [21603619]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.22%
—
—
—
—
—
—
6
6
266
2765
azathioprine; oral, parenteral
L04AX01 [21603927]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.84%
controls:0.18%
—
—
—
—
—
—
5
5
267
2766
Epilepsy and comparable convulsive disorders
111 [2001600111]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.84%
controls:0.18%
—
—
—
—
—
—
5
5
267
2766
X-ray examination of the lungs in one projection
GD1PA [2001303645]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.16%
—
—
—
—
—
—
—
5
5
304
3122
—
Stroke/cerebrovascular accident
K90 [2002000617]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.16%
—
—
—
—
—
—
—
5
5
304
3122
—
amlodipine; oral
C08CA01 [21601747]
6.5e-01
8.5e-01
8.6e-01
—
3.0e-01
7.4e-01
7.4e-01
cases:10.59%
controls:5.80%
cases:10.25%
controls:4.66%
cases:3.42%
controls:1.47%
—
—
cases:1.56%
controls:1.16%
cases:9.71%
controls:4.89%
cases:13.24%
controls:6.78%
34
185
287
3005
33
149
289
3047
11
47
311
3149
—
5
37
315
3152
30
153
279
2974
36
188
236
2583
Oncology Clinic/Center
261QX0200X [38004268]
9.8e-01
1.3e+00
—
—
—
—
5.8e-02
cases:8.72%
controls:3.45%
cases:4.04%
controls:1.10%
—
—
—
—
—
—
—
—
cases:4.04%
controls:3.83%
28
110
293
3080
13
35
309
3161
—
—
—
—
11
106
261
2665
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
—
2.3e+00
—
—
—
—
—
—
—
cases:2.17%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
7
7
315
3189
—
—
—
—
—
Scheduled procedure
ZXD10 [2001311387]
3.1e-01
7.4e-01
2.3e+00
—
—
1.3e+00
6.6e-01
cases:6.54%
controls:4.89%
cases:3.42%
controls:1.66%
cases:1.86%
controls:0.19%
—
—
—
—
cases:3.24%
controls:0.90%
cases:7.72%
controls:4.15%
21
156
300
3034
11
53
311
3143
6
6
316
3190
—
—
10
28
299
3099
21
115
251
2656
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
1.1e+00
2.3e+00
—
—
—
6.7e-01
1.1e+00
cases:2.49%
controls:0.82%
cases:1.86%
controls:0.19%
—
—
—
—
—
—
cases:1.62%
controls:0.83%
cases:4.41%
controls:1.55%
8
26
313
3164
6
6
316
3190
—
—
—
5
26
304
3101
12
43
260
2728
Emergency Room and Inpatient Visit
ERIP [262]
9.3e-01
1.4e+00
—
1.0e+50
1.8e+00
7.8e-01
6.6e-01
cases:6.85%
controls:2.82%
cases:5.28%
controls:1.41%
—
—
cases:4.04%
controls:0.00%
cases:1.56%
controls:0.25%
cases:4.21%
controls:1.98%
cases:11.40%
controls:6.21%
22
90
299
3100
17
45
305
3151
—
13
0
309
3196
5
8
315
3181
13
62
296
3065
31
172
241
2599
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
1.2e+00
8.8e-01
—
—
—
9.5e-01
1.1e+00
cases:6.85%
controls:2.10%
cases:3.11%
controls:1.31%
—
—
—
—
—
—
cases:2.91%
controls:1.15%
cases:6.62%
controls:2.42%
22
67
299
3123
10
42
312
3154
—
—
—
9
36
300
3091
18
67
254
2704
Depressive episode
F32 [45595904]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.36%
—
—
—
—
—
—
9
10
263
2761
levetiracetam; oral, parenteral
N03AX14 [21604436]
—
—
—
—
—
1.3e+00
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.45%
cases:2.94%
controls:0.32%
—
—
—
—
—
5
14
304
3113
8
9
264
2762
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.32%
—
—
—
—
—
—
8
9
264
2762
Treatment plan or consultation
WZC00 [2001310885]
6.4e-01
1.1e+00
-1.0e+50
—
—
8.0e-01
1.1e+00
cases:7.79%
controls:4.26%
cases:4.35%
controls:1.44%
cases:0.00%
controls:0.16%
—
—
—
—
cases:3.88%
controls:1.79%
cases:13.60%
controls:5.05%
25
136
296
3054
14
46
308
3150
0
5
322
3191
—
—
12
56
297
3071
37
140
235
2631
Special examination, unspecified
Z01.9 [45576123]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.25%
—
—
—
—
—
—
6
7
266
2764
Counselling and guidance which enhance independent living
R2130 [2001310196]
8.6e-01
1.4e+00
—
—
—
2.2e+00
1.0e+00
cases:2.49%
controls:1.07%
cases:1.55%
controls:0.41%
—
—
—
—
—
—
cases:1.94%
controls:0.22%
cases:2.94%
controls:1.08%
8
34
313
3156
5
13
317
3183
—
—
—
6
7
303
3120
8
30
264
2741
pH of Blood
11558-4 [3010421]
1.5e+00
2.3e+00
—
—
—
2.2e+00
1.9e+00
cases:1.87%
controls:0.41%
cases:1.55%
controls:0.16%
—
—
—
—
—
—
cases:1.94%
controls:0.22%
cases:2.21%
controls:0.32%
6
13
315
3177
5
5
317
3191
—
—
—
6
7
303
3120
6
9
266
2762
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
1.0e+00
2.2e+00
—
—
—
—
1.2e+00
cases:2.80%
controls:1.00%
cases:1.86%
controls:0.22%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.19%
9
32
312
3158
6
7
316
3189
—
—
—
—
10
33
262
2738
Kolposcopy
ULA02 [2001306679]
—
2.2e+00
—
—
—
1.3e+00
—
—
—
cases:1.86%
controls:0.22%
—
—
—
—
—
—
cases:1.62%
controls:0.45%
—
—
—
6
7
316
3189
—
—
—
5
14
304
3113
—
Ultrasound examination of uterus and parametria
LC2AE [2001306543]
—
2.2e+00
—
—
—
—
9.0e-01
—
—
cases:1.86%
controls:0.22%
—
—
—
—
—
—
—
—
cases:1.84%
controls:0.76%
—
6
7
316
3189
—
—
—
—
5
21
267
2750
lidocaine; ointment
D04AB01 [21602020]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.40%
—
—
—
—
—
—
9
11
263
2760
lidocaine
C05AD01 [21601618]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.40%
—
—
—
—
—
—
9
11
263
2760
Multiple sclerosis
G35 [45571794]
2.1e+00
1.9e+00
—
—
—
—
1.5e+00
cases:2.49%
controls:0.31%
cases:1.86%
controls:0.28%
—
—
—
—
—
—
—
—
cases:1.84%
controls:0.40%
8
10
313
3180
6
9
316
3187
—
—
—
—
5
11
267
2760
Irritable bowel syndrome with diarrhoea
K58.0 [45596336]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.57%
controls:0.32%
—
—
—
—
—
—
7
9
265
2762
Insertion of intrauterine device
TLC00 [2001306647]
—
-1.0e+50
—
—
—
—
2.1e+00
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
cases:2.57%
controls:0.32%
—
0
6
322
3190
—
—
—
—
7
9
265
2762
Hospital outpatient
ZY010 [2001311599]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.57%
controls:0.32%
—
—
—
—
—
—
7
9
265
2762
Incontinence urine
U04 [2002001139]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.57%
controls:0.32%
—
—
—
—
—
—
7
9
265
2762
oxybutynin; oral, transdermal
G04BD04 [21602637]
2.1e+00
—
—
—
—
—
—
cases:2.18%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
314
3181
—
—
—
—
—
—
clidinium and psycholeptics
A03CA02 [21600204]
2.1e+00
—
—
—
—
—
7.2e-01
cases:2.18%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:1.84%
controls:0.90%
7
9
314
3181
—
—
—
—
—
5
25
267
2746
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
1.4e+00
2.1e+00
—
—
—
—
—
cases:1.56%
controls:0.41%
cases:2.17%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
5
13
316
3177
7
9
315
3187
—
—
—
—
—
Need for immunization against other specified single viral diseases
Z25.8 [45547296]
6.6e-01
2.1e+00
—
—
—
1.2e+00
2.7e-01
cases:1.87%
controls:0.97%
cases:2.17%
controls:0.28%
—
—
—
—
—
—
cases:1.62%
controls:0.48%
cases:2.21%
controls:1.70%
6
31
315
3159
7
9
315
3187
—
—
—
5
15
304
3112
6
47
266
2724
methenamine; oral
J01XX05 [21603065]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.29%
—
—
—
—
—
—
6
8
266
2763
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
1.3e+00
1.6e+00
—
—
—
2.0e+00
9.5e-01
cases:2.49%
controls:0.66%
cases:1.86%
controls:0.38%
—
—
—
—
—
—
cases:1.94%
controls:0.26%
cases:2.21%
controls:0.87%
8
21
313
3169
6
12
316
3184
—
—
—
6
8
303
3119
6
24
266
2747
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.6e-01
4.3e-01
9.9e-01
—
1.0e+00
2.0e-01
1.9e-01
cases:25.86%
controls:22.98%
cases:23.60%
controls:16.74%
cases:7.76%
controls:3.04%
—
—
cases:8.13%
controls:3.04%
cases:21.68%
controls:18.42%
cases:39.34%
controls:35.01%
83
733
238
2457
76
535
246
2661
25
97
297
3099
—
26
97
294
3092
67
576
242
2551
107
970
165
1801
Rehabilitation Hospital
283X00000X [38004285]
2.0e+00
—
—
—
—
—
—
cases:1.87%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
315
3182
—
—
—
—
—
—
Rheumatology
66 [38004491]
2.2e-01
1.2e-01
—
—
—
1.0e+00
9.9e-01
cases:3.43%
controls:2.76%
cases:1.86%
controls:1.66%
—
—
—
—
—
—
cases:4.85%
controls:1.79%
cases:7.35%
controls:2.85%
11
88
310
3102
6
53
316
3143
—
—
—
15
56
294
3071
20
79
252
2692
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
1.4e+00
2.0e+00
—
—
—
—
6.1e-01
cases:2.49%
controls:0.60%
cases:1.86%
controls:0.25%
—
—
—
—
—
—
—
—
cases:1.84%
controls:1.01%
8
19
313
3171
6
8
316
3188
—
—
—
—
5
28
267
2743
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
1.3e+00
2.0e+00
—
—
—
—
6.8e-01
cases:2.18%
controls:0.63%
cases:1.86%
controls:0.25%
—
—
—
—
—
—
—
—
cases:1.84%
controls:0.94%
7
20
314
3170
6
8
316
3188
—
—
—
—
5
26
267
2745
Bacterial infection, unspecified
A49.9 [45590816]
—
—
—
—
—
2.1e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.19%
cases:3.68%
controls:0.51%
—
—
—
—
—
5
6
304
3121
10
14
262
2757
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
1.2e+00
2.0e+00
—
—
—
1.3e+00
8.8e-01
cases:2.18%
controls:0.69%
cases:2.48%
controls:0.34%
—
—
—
—
—
—
cases:1.94%
controls:0.54%
cases:2.57%
controls:1.08%
7
22
314
3168
8
11
314
3185
—
—
—
6
17
303
3110
7
30
265
2741
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
3.8e-01
7.6e-01
1.2e+00
—
1.4e-01
2.9e-01
3.4e-01
cases:22.74%
controls:16.80%
cases:22.05%
controls:11.64%
cases:5.90%
controls:1.81%
—
—
cases:1.88%
controls:1.63%
cases:16.18%
controls:12.60%
cases:35.29%
controls:28.00%
73
536
248
2654
71
372
251
2824
19
58
303
3138
—
6
52
314
3137
50
394
259
2733
96
776
176
1995
Cervical disc disorder with radiculopathy
M50.1 [45596588]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.57%
controls:0.36%
—
—
—
—
—
—
7
10
265
2761
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
8.9e-01
7.4e-01
—
—
—
9.7e-02
1.1e+00
cases:6.23%
controls:2.66%
cases:3.42%
controls:1.66%
—
—
—
—
—
—
cases:1.62%
controls:1.47%
cases:11.03%
controls:3.97%
20
85
301
3105
11
53
311
3143
—
—
—
5
46
304
3081
30
110
242
2661
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.47%
—
—
—
—
—
—
9
13
263
2758
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
6.8e-01
8.2e-01
1.5e+00
—
—
1.2e+00
8.0e-01
cases:9.66%
controls:5.14%
cases:4.35%
controls:1.97%
cases:2.17%
controls:0.47%
—
—
—
—
cases:4.21%
controls:1.34%
cases:11.76%
controls:5.63%
31
164
290
3026
14
63
308
3133
7
15
315
3181
—
—
13
42
296
3085
32
156
240
2615
Pediatric Medicine
37 [38004477]
1.6e-01
6.6e-01
1.4e+00
—
2.0e+00
5.9e-01
6.3e-01
cases:3.74%
controls:3.20%
cases:3.11%
controls:1.63%
cases:1.55%
controls:0.41%
—
—
cases:2.19%
controls:0.31%
cases:2.91%
controls:1.63%
cases:4.04%
controls:2.20%
12
102
309
3088
10
52
312
3144
5
13
317
3183
—
7
10
313
3179
9
51
300
3076
11
61
261
2710
Poisoning by systemic antibiotics
T36 [45756588]
2.0e+00
—
—
—
—
—
—
cases:2.80%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
9
13
312
3177
—
—
—
—
—
—
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
5.9e-01
1.0e+00
—
—
—
8.7e-01
4.3e-01
cases:9.97%
controls:5.80%
cases:5.90%
controls:2.16%
—
—
—
—
—
—
cases:6.47%
controls:2.81%
cases:10.29%
controls:6.93%
32
185
289
3005
19
69
303
3127
—
—
—
20
88
289
3039
28
192
244
2579
Flexible laryngoscopy
UDQ12 [2001301827]
1.9e+00
—
—
—
—
—
—
cases:2.18%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
314
3179
—
—
—
—
—
—
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
—
—
—
—
—
1.8e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.42%
cases:3.68%
controls:1.08%
—
—
—
—
—
8
13
301
3114
10
30
262
2741
dydrogesterone; oral
G03DB01 [21602544]
6.4e-01
1.7e+00
—
—
—
1.3e+00
1.8e+00
cases:3.12%
controls:1.66%
cases:2.17%
controls:0.41%
—
—
—
—
—
—
cases:1.94%
controls:0.51%
cases:5.88%
controls:0.97%
10
53
311
3137
7
13
315
3183
—
—
—
6
16
303
3111
16
27
256
2744
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 [3034780]
1.8e+00
—
—
—
—
—
1.5e+00
cases:2.49%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.65%
8
13
313
3177
—
—
—
—
—
8
18
264
2753
Person encountering health services in unspecified circumstances
Z76.9 [45609967]
9.2e-01
—
—
—
—
1.4e+00
1.8e+00
cases:1.87%
controls:0.75%
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.42%
cases:4.04%
controls:0.69%
6
24
315
3166
—
—
—
—
5
13
304
3114
11
19
261
2752
General medical examination
Z00.0 [45585791]
3.7e-01
1.5e+00
—
—
—
1.8e+00
3.6e-02
cases:3.12%
controls:2.16%
cases:1.86%
controls:0.41%
—
—
—
—
—
—
cases:2.59%
controls:0.45%
cases:2.21%
controls:2.13%
10
69
311
3121
6
13
316
3183
—
—
—
8
14
301
3113
6
59
266
2712
Uroflowmetry
44856007 [4261340]
4.1e-01
1.8e+00
—
—
—
—
1.1e+00
cases:1.87%
controls:1.25%
cases:2.17%
controls:0.38%
—
—
—
—
—
—
—
—
cases:3.31%
controls:1.12%
6
40
315
3150
7
12
315
3184
—
—
—
—
9
31
263
2740
Sensorineural hearing loss, bilateral
H90.3 [45576850]
6.4e-01
1.8e+00
—
—
—
9.9e-01
7.5e-01
cases:2.80%
controls:1.50%
cases:2.17%
controls:0.38%
—
—
—
—
—
—
cases:1.62%
controls:0.61%
cases:4.04%
controls:1.95%
9
48
312
3142
7
12
315
3184
—
—
—
5
19
304
3108
11
54
261
2717
ECG with 12 standard connections
XF400 [2001303368]
-4.0e-02
1.8e+00
—
—
—
—
1.2e+00
cases:1.87%
controls:1.94%
cases:2.17%
controls:0.38%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.12%
6
62
315
3128
7
12
315
3184
—
—
—
—
10
31
262
2740
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.0e-01
1.8e+00
—
1.0e+50
—
—
1.1e+00
cases:1.56%
controls:1.41%
cases:2.17%
controls:0.38%
—
—
cases:1.55%
controls:0.00%
—
—
—
—
cases:3.31%
controls:1.12%
5
45
316
3145
7
12
315
3184
—
5
0
317
3196
—
—
9
31
263
2740
Urgent procedure
ZXD05 [2001311386]
6.8e-01
1.8e+00
—
—
—
—
9.4e-01
cases:7.17%
controls:3.76%
cases:3.73%
controls:0.66%
—
—
—
—
—
—
—
—
cases:5.88%
controls:2.38%
23
120
298
3070
12
21
310
3175
—
—
—
—
16
66
256
2705
Depressive episode, unspecified
F32.9 [45571760]
-1.4e-01
1.8e+00
—
—
—
—
1.5e-01
cases:1.56%
controls:1.79%
cases:2.48%
controls:0.44%
—
—
—
—
—
—
—
—
cases:2.21%
controls:1.91%
5
57
316
3133
8
14
314
3182
—
—
—
—
6
53
266
2718
esomeprazole; oral, parenteral
A02BC05 [21600100]
5.6e-01
7.7e-01
—
—
—
8.8e-01
8.5e-01
cases:11.84%
controls:7.15%
cases:6.21%
controls:2.97%
—
—
—
—
—
—
cases:6.80%
controls:2.94%
cases:15.07%
controls:7.04%
38
228
283
2962
20
95
302
3101
—
—
—
21
92
288
3035
41
195
231
2576
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
—
—
—
—
—
1.7e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.48%
cases:4.04%
controls:1.34%
—
—
—
—
—
8
15
301
3112
11
37
261
2734
salmeterol and fluticasone
R03AK06 [21603280]
7.1e-01
7.0e-01
1.7e+00
—
—
9.1e-01
8.6e-01
cases:4.67%
controls:2.35%
cases:3.11%
controls:1.56%
cases:2.48%
controls:0.47%
—
—
—
—
cases:3.88%
controls:1.60%
cases:5.15%
controls:2.24%
15
75
306
3115
10
50
312
3146
8
15
314
3181
—
—
12
50
297
3077
14
62
258
2709
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1.3e+00
1.7e+00
—
1.0e+50
—
1.7e+00
1.7e+00
cases:2.49%
controls:0.72%
cases:2.17%
controls:0.41%
—
—
cases:1.55%
controls:0.00%
—
—
cases:1.62%
controls:0.29%
cases:4.04%
controls:0.79%
8
23
313
3167
7
13
315
3183
—
5
0
317
3196
—
5
9
304
3118
11
22
261
2749
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
4.5e-01
9.2e-01
—
—
—
9.0e-01
7.4e-01
cases:8.41%
controls:5.52%
cases:5.59%
controls:2.32%
—
—
—
—
—
—
cases:5.18%
controls:2.17%
cases:13.24%
controls:6.78%
27
176
294
3014
18
74
304
3122
—
—
—
16
68
293
3059
36
188
236
2583
Taking care of patient’s/customer’s hygiene
SPAT1137 [2001700238]
1.6e+00
—
—
—
—
1.6e+00
1.7e+00
cases:1.56%
controls:0.31%
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.32%
cases:2.94%
controls:0.58%
5
10
316
3180
—
—
—
—
5
10
304
3117
8
16
264
2755
Nausea and vomiting
R11 [45539317]
9.2e-01
2.1e+00
—
—
—
—
1.7e+00
cases:1.87%
controls:0.75%
cases:1.55%
controls:0.19%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.58%
6
24
315
3166
5
6
317
3190
—
—
—
—
8
16
264
2755
Tissue Pathology biopsy report
66121-5 [40768804]
6.7e-01
9.7e-01
—
—
—
2.4e-01
2.0e-01
cases:10.28%
controls:5.52%
cases:5.28%
controls:2.07%
—
—
—
—
—
—
cases:2.59%
controls:2.05%
cases:8.09%
controls:6.71%
33
176
288
3014
17
66
305
3130
—
—
—
8
64
301
3063
22
186
250
2585
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
9.9e-01
—
—
—
—
1.6e+00
8.2e-01
cases:4.36%
controls:1.66%
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.51%
cases:4.41%
controls:1.98%
14
53
307
3137
—
—
—
—
8
16
301
3111
12
55
260
2716
Fever, unspecified
R50.9 [45582716]
1.7e-01
2.1e+00
—
—
—
2.1e+00
1.6e+00
cases:1.56%
controls:1.32%
cases:1.55%
controls:0.19%
—
—
—
—
—
—
cases:1.62%
controls:0.19%
cases:6.25%
controls:1.30%
5
42
316
3148
5
6
317
3190
—
—
—
5
6
304
3121
17
36
255
2735
Nonallergic asthma
J45.1 [45557625]
9.6e-01
1.8e+00
—
—
—
1.7e+00
1.6e+00
cases:1.87%
controls:0.72%
cases:1.86%
controls:0.31%
—
—
—
—
—
—
cases:1.94%
controls:0.35%
cases:3.68%
controls:0.76%
6
23
315
3167
6
10
316
3186
—
—
—
6
11
303
3116
10
21
262
2750
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
4.9e-01
5.9e-01
7.8e-01
—
4.3e-01
4.9e-01
5.1e-01
cases:35.83%
controls:25.49%
cases:20.50%
controls:12.45%
cases:4.97%
controls:2.35%
—
—
cases:3.75%
controls:2.48%
cases:21.04%
controls:13.98%
cases:44.12%
controls:32.19%
115
813
206
2377
66
398
256
2798
16
75
306
3121
—
12
79
308
3110
65
437
244
2690
120
892
152
1879
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
8.2e-01
7.6e-01
—
—
-1.0e+50
3.7e-01
7.6e-01
cases:9.66%
controls:4.51%
cases:3.11%
controls:1.47%
—
—
—
—
cases:0.00%
controls:0.19%
cases:1.94%
controls:1.34%
cases:9.56%
controls:4.69%
31
144
290
3046
10
47
312
3149
—
—
0
6
320
3183
6
42
303
3085
26
130
246
2641
epinephrine
S01EA01 [21603673]
5.7e-01
1.5e+00
—
—
—
1.5e+00
1.6e+00
cases:1.87%
controls:1.07%
cases:1.86%
controls:0.44%
—
—
—
—
—
—
cases:2.27%
controls:0.51%
cases:4.04%
controls:0.87%
6
34
315
3156
6
14
316
3182
—
—
—
7
16
302
3111
11
24
261
2747
epinephrine; parenteral
C01CA24 [21600303]
5.7e-01
1.5e+00
—
—
—
1.5e+00
1.6e+00
cases:1.87%
controls:1.07%
cases:1.86%
controls:0.44%
—
—
—
—
—
—
cases:2.27%
controls:0.51%
cases:4.04%
controls:0.87%
6
34
315
3156
6
14
316
3182
—
—
—
7
16
302
3111
11
24
261
2747
sodium fluoride; oral
A01AA01 [21600005]
1.5e+00
—
—
—
—
—
8.0e-01
cases:3.43%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
cases:1.84%
controls:0.83%
11
24
310
3166
—
—
—
—
—
5
23
267
2748
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
7.0e-01
1.6e+00
—
—
—
1.6e+00
1.5e+00
cases:1.87%
controls:0.94%
cases:2.48%
controls:0.53%
—
—
—
—
—
—
cases:1.94%
controls:0.42%
cases:5.15%
controls:1.15%
6
30
315
3160
8
17
314
3179
—
—
—
6
13
303
3114
14
32
258
2739
risperidone; oral, parenteral
N05AX08 [21604559]
1.5e+00
1.4e+00
—
—
—
—
6.3e-01
cases:2.80%
controls:0.63%
cases:1.86%
controls:0.47%
—
—
—
—
—
—
—
—
cases:2.21%
controls:1.19%
9
20
312
3170
6
15
316
3181
—
—
—
—
6
33
266
2738
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
1.0e+00
—
—
—
—
—
1.5e+00
cases:2.18%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.83%
7
25
314
3165
—
—
—
—
—
10
23
262
2748
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
1.5e+00
—
—
—
—
—
1.1e+00
cases:4.67%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.23%
15
34
306
3156
—
—
—
—
—
10
34
262
2737
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
5.9e-01
1.5e+00
—
—
—
—
6.5e-01
cases:2.80%
controls:1.57%
cases:3.73%
controls:0.84%
—
—
—
—
—
—
—
—
cases:5.15%
controls:2.74%
9
50
312
3140
12
27
310
3169
—
—
—
—
14
76
258
2695
mirabegron; oral
G04BD12 [43534790]
1.5e+00
1.4e+00
—
—
—
—
9.1e-01
cases:4.36%
controls:1.00%
cases:2.17%
controls:0.53%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.52%
14
32
307
3158
7
17
315
3179
—
—
—
—
10
42
262
2729
Localized oedema
R60.0 [45597193]
1.5e+00
1.5e+00
—
—
—
—
—
cases:3.43%
controls:0.78%
cases:1.55%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
11
25
310
3165
5
11
317
3185
—
—
—
—
—
Other senile cataract
H25.8 [45605644]
—
-1.0e+50
—
—
—
—
1.5e+00
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.76%
—
0
11
322
3185
—
—
—
—
9
21
263
2750
dexamethasone; oral, parenteral
H02AB02 [21602730]
7.0e-01
8.7e-01
—
—
—
1.5e+00
-5.9e-02
cases:2.80%
controls:1.41%
cases:1.55%
controls:0.66%
—
—
—
—
—
—
cases:2.91%
controls:0.67%
cases:1.84%
controls:1.95%
9
45
312
3145
5
21
317
3175
—
—
—
9
21
300
3106
5
54
267
2717
duloxetine; oral
N06AX21 [21604749]
5.7e-01
1.4e+00
—
—
—
1.5e+00
1.0e+00
cases:2.80%
controls:1.60%
cases:2.48%
controls:0.59%
—
—
—
—
—
—
cases:3.24%
controls:0.77%
cases:4.04%
controls:1.52%
9
51
312
3139
8
19
314
3177
—
—
—
10
24
299
3103
11
42
261
2729
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
7.4e-01
1.5e+00
—
—
—
6.1e-01
7.0e-01
cases:5.30%
controls:2.60%
cases:3.42%
controls:0.81%
—
—
—
—
—
—
cases:3.24%
controls:1.79%
cases:8.46%
controls:4.37%
17
83
304
3107
11
26
311
3170
—
—
—
10
56
299
3071
23
121
249
2650
General anaesthesia
WX402 [2001310806]
5.1e-01
1.5e+00
—
—
—
—
9.4e-01
cases:2.49%
controls:1.50%
cases:4.04%
controls:0.97%
—
—
—
—
—
—
—
—
cases:5.88%
controls:2.38%
8
48
313
3142
13
31
309
3165
—
—
—
—
16
66
256
2705
Supine thorax X-ray examination
GD1QA [2001303648]
2.7e-01
—
2.1e+00
1.0e+50
—
1.1e+00
1.5e+00
cases:1.56%
controls:1.19%
—
—
cases:1.55%
controls:0.19%
cases:1.86%
controls:0.00%
—
—
cases:1.94%
controls:0.64%
cases:5.88%
controls:1.44%
5
38
316
3152
—
5
6
317
3190
6
0
316
3196
—
6
20
303
3107
16
40
256
2731
Limited function/disability (L)
L28 [2002000647]
4.9e-01
1.2e+00
—
—
—
1.1e+00
1.4e+00
cases:2.18%
controls:1.35%
cases:2.48%
controls:0.78%
—
—
—
—
—
—
cases:2.27%
controls:0.80%
cases:6.99%
controls:1.77%
7
43
314
3147
8
25
314
3171
—
—
—
7
25
302
3102
19
49
253
2722
Functional capacity evaluation
443351003 [40481051]
8.4e-01
1.4e+00
—
—
—
1.2e+00
1.4e+00
cases:3.43%
controls:1.50%
cases:1.86%
controls:0.47%
—
—
—
—
—
—
cases:2.27%
controls:0.70%
cases:5.88%
controls:1.48%
11
48
310
3142
6
15
316
3181
—
—
—
7
22
302
3105
16
41
256
2730
Other investigative procedure of eye
XCW99 [2001301491]
1.4e+00
—
—
—
—
1.5e+00
1.1e+00
cases:3.43%
controls:0.85%
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.35%
cases:3.31%
controls:1.15%
11
27
310
3163
—
—
—
—
5
11
304
3116
9
32
263
2739
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4.2e-01
8.1e-01
1.3e+00
—
1.1e+00
3.4e-01
6.0e-01
cases:18.07%
controls:12.63%
cases:13.66%
controls:6.57%
cases:3.11%
controls:0.91%
—
—
cases:2.81%
controls:0.97%
cases:10.36%
controls:7.58%
cases:28.68%
controls:18.08%
58
403
263
2787
44
210
278
2986
10
29
312
3167
—
9
31
311
3158
32
237
277
2890
78
501
194
2270
Urinary tract infection, site not specified
N39.0 [45548665]
9.3e-01
—
—
—
—
1.6e+00
1.4e+00
cases:2.80%
controls:1.13%
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.32%
cases:6.25%
controls:1.62%
9
36
312
3154
—
—
—
—
5
10
304
3117
17
45
255
2726
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
5.1e-01
5.5e-01
5.6e-01
—
3.8e-01
6.6e-01
7.3e-01
cases:19.00%
controls:12.38%
cases:14.60%
controls:9.01%
cases:3.73%
controls:2.16%
—
—
cases:3.44%
controls:2.38%
cases:16.83%
controls:9.43%
cases:26.47%
controls:14.80%
61
395
260
2795
47
288
275
2908
12
69
310
3127
—
11
76
309
3113
52
295
257
2832
72
410
200
2361
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
7.6e-01
7.6e-01
—
—
—
1.6e+00
1.4e+00
cases:3.43%
controls:1.63%
cases:1.86%
controls:0.88%
—
—
—
—
—
—
cases:2.27%
controls:0.45%
cases:7.72%
controls:2.06%
11
52
310
3138
6
28
316
3168
—
—
—
7
14
302
3113
21
57
251
2714
Respiratory and circulatory monitoring
WX700 [2001310817]
6.9e-01
1.3e+00
—
—
—
—
1.4e+00
cases:4.05%
controls:2.07%
cases:2.48%
controls:0.69%
—
—
—
—
—
—
—
—
cases:4.78%
controls:1.26%
13
66
308
3124
8
22
314
3174
—
—
—
—
13
35
259
2736
No procedures
SPAT1301 [2001700402]
6.9e-01
1.4e+00
—
—
—
4.3e-01
4.7e-01
cases:8.41%
controls:4.42%
cases:4.35%
controls:1.16%
—
—
—
—
—
—
cases:2.91%
controls:1.92%
cases:7.35%
controls:4.73%
27
141
294
3049
14
37
308
3159
—
—
—
9
60
300
3067
20
131
252
2640
Vertigo/dizziness
N17 [2002000728]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.04%
controls:1.08%
—
—
—
—
—
—
11
30
261
2741
Medical doctor
Z2221 [2001311556]
1.2e-01
1.3e+00
—
—
—
1.3e+00
8.0e-01
cases:4.05%
controls:3.61%
cases:3.73%
controls:1.00%
—
—
—
—
—
—
cases:3.56%
controls:1.02%
cases:5.88%
controls:2.74%
13
115
308
3075
12
32
310
3164
—
—
—
11
32
298
3095
16
76
256
2695
Specific gravity of Urine by Refractometry
5810-7 [3019150]
5.3e-01
1.3e+00
1.8e+00
—
—
8.7e-01
1.0e-01
cases:5.30%
controls:3.20%
cases:5.28%
controls:1.44%
cases:1.86%
controls:0.31%
—
—
—
—
cases:4.53%
controls:1.95%
cases:6.99%
controls:6.35%
17
102
304
3088
17
46
305
3150
6
10
316
3186
—
—
14
61
295
3066
19
176
253
2595
Cystoscopy
UKC02 [2001306005]
1.3e+00
1.3e+00
—
—
—
1.3e+00
7.8e-01
cases:4.36%
controls:1.19%
cases:1.55%
controls:0.44%
—
—
—
—
—
—
cases:1.62%
controls:0.45%
cases:2.94%
controls:1.37%
14
38
307
3152
5
14
317
3182
—
—
—
5
14
304
3113
8
38
264
2733
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
1.5e+00
1.5e+00
—
—
—
-1.0e+50
1.3e+00
cases:2.18%
controls:0.50%
cases:1.86%
controls:0.44%
—
—
—
—
—
—
cases:0.00%
controls:0.42%
cases:4.04%
controls:1.12%
7
16
314
3174
6
14
316
3182
—
—
—
0
13
309
3114
11
31
261
2740
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
9.6e-01
—
—
—
—
1.4e+00
1.3e+00
cases:4.67%
controls:1.85%
—
—
—
—
—
—
—
—
cases:1.94%
controls:0.48%
cases:4.78%
controls:1.37%
15
59
306
3131
—
—
—
—
6
15
303
3112
13
38
259
2733
Telehealth
OMOP5556618 [722455]
3.3e-01
3.7e-01
7.4e-01
—
1.3e+00
7.1e-02
1.8e-01
cases:23.99%
controls:18.53%
cases:10.87%
controls:7.79%
cases:3.11%
controls:1.50%
—
—
cases:4.38%
controls:1.29%
cases:8.74%
controls:8.19%
cases:19.85%
controls:17.11%
77
591
244
2599
35
249
287
2947
10
48
312
3148
—
14
41
306
3148
27
256
282
2871
54
474
218
2297
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
2.0e-01
9.7e-01
—
—
1.8e+00
1.2e+00
5.2e-01
cases:3.12%
controls:2.57%
cases:4.66%
controls:1.81%
—
—
—
—
cases:1.56%
controls:0.25%
cases:4.53%
controls:1.38%
cases:7.35%
controls:4.51%
10
82
311
3108
15
58
307
3138
—
—
5
8
315
3181
14
43
295
3084
20
125
252
2646
lercanidipine; oral
C08CA13 [21601759]
1.3e-01
8.2e-01
—
—
—
9.5e-01
1.2e+00
cases:2.18%
controls:1.91%
cases:3.42%
controls:1.53%
—
—
—
—
—
—
cases:3.56%
controls:1.41%
cases:6.62%
controls:2.06%
7
61
314
3129
11
49
311
3147
—
—
—
11
44
298
3083
18
57
254
2714
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
6.1e-01
1.4e+00
—
—
—
1.4e+00
1.2e+00
cases:3.12%
controls:1.72%
cases:2.48%
controls:0.59%
—
—
—
—
—
—
cases:2.59%
controls:0.67%
cases:8.09%
controls:2.56%
10
55
311
3135
8
19
314
3177
—
—
—
8
21
301
3106
22
71
250
2700
Bilateral
ZXA10 [2001311348]
1.2e-01
—
—
—
—
—
1.2e+00
cases:2.18%
controls:1.94%
—
—
—
—
—
—
—
—
—
—
cases:4.78%
controls:1.48%
7
62
314
3128
—
—
—
—
—
13
41
259
2730
Administration of medicine
SPAT1254 [2001700355]
8.6e-01
1.4e+00
—
—
—
1.1e+00
1.2e+00
cases:3.12%
controls:1.35%
cases:2.17%
controls:0.56%
—
—
—
—
—
—
cases:1.94%
controls:0.67%
cases:4.78%
controls:1.55%
10
43
311
3147
7
18
315
3178
—
—
—
6
21
303
3106
13
43
259
2728

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
151
31
84.20
273.40
4.0
1.2
294.92
272.39
mosm/kgh2o
2.51
130
23
190
317
11.78
124.01
6.0
1.8
307.63
388.14
nmol/l
4.84
180
298
199
572
6.66
71.42
4.0
2.7
449.00
520.74
mosm/kgh2o
4.11
179
499
68
82
10.03
54.15
2.5
1.1
7.66
8.75
u/l
0.28
53
64
278
1484
5.07
38.71
11.8
7.1
1.22
1.21
mmol/l
0.66
237
1292
42
47
10.00
34.92
2.6
1.4
0.24
0.32
nmol/l
0.62
30
37
252
1344
4.04
32.77
11.9
6.6
1.21
1.21
mmol/l
0.16
236
1253
47
68
7.82
31.76
2.0
1.2
—
—
—
0
0
82
229
4.36
27.15
4.9
2.1
13.92
14.02
nmol/l
0.03
75
214
44
77
6.38
24.79
1.9
1.2
317.03
15.33
e6/l
0.48
31
57
186
928
3.12
24.56
5.9
3.6
7.39
7.40
ph
0.31
139
653
28
29
10.40
24.42
2.2
1.0
—
—
—
0
0
44
79
6.22
24.15
1.9
1.3
1039.84
148.85
e6/l
0.85
32
60
62
159
4.51
22.71
2.4
1.3
14.38
22.21
iu/l
1.10
50
130
29
15
20.94
19.86
1.2
1.1
157.48
163.04
mmol/24h
0.08
29
15
90
331
3.31
19.43
10.6
10.6
7.42
7.42
ph
0.25
56
191
222
1331
2.79
19.22
5.3
4.6
35.25
36.29
g/l
1.75
217
1269
86
329
3.13
17.21
10.5
10.6
0.65
0.88
mmol/l
0.20
71
283
246
1658
2.59
15.17
6.4
6.4
9.13
11.05
umol/l
4.12
239
1581
92
394
2.80
14.84
10.6
7.5
105.79
104.28
mmol/l
1.09
92
394
259
1802
2.63
14.71
9.3
5.0
6.63
6.59
mmol/l
0.10
247
1702
99
450
2.67
14.15
2.7
2.2
2.39
2.34
g/l
0.32
94
418
29
60
5.18
13.57
2.0
1.8
0.70
0.85
g/l
0.21
22
48
168
992
2.32
13.40
3.3
2.5
76.07
66.16
u/l
0.17
154
916
54
188
3.21
12.45
5.4
4.1
7.42
7.42
ph
0.21
41
158
22
39
5.95
12.10
2.0
1.3
—
—
—
0
0
307
2426
3.00
11.82
9.9
4.3
15.07
14.67
pmol/l
1.79
297
2232
139
790
2.25
11.81
5.9
4.0
—
—
—
0
0
149
884
2.18
11.26
4.3
2.9
—
—
—
0
0
68
285
2.72
11.21
7.2
3.7
7.38
7.39
ph
0.87
39
164
169
1059
2.14
11.05
8.4
5.5
—
—
—
0
0
53
196
3.00
10.99
10.0
8.1
24.39
24.86
mmol/l
0.38
53
196
66
276
2.71
10.91
7.6
3.6
1.65
1.79
mmol/l
0.15
60
241
200
1360
2.08
10.27
9.8
10.8
1.10
1.19
inr
2.54
172
1101
60
250
2.69
9.95
13.4
10.5
—
—
—
0
0
139
848
2.05
9.39
3.6
2.9
0.75
0.35
e6/l
0.38
112
610
57
243
2.60
9.00
2.5
2.9
77.00
70.72
e9/l
0.89
43
174
128
771
2.03
8.85
2.4
2.0
2.69
2.94
mg/l
0.61
116
674
293
2382
2.34
8.51
10.5
7.8
78.95
77.95
u/l
0.18
285
2257
197
1397
1.92
8.30
4.0
2.4
77.30
76.65
nmol/l
0.12
184
1258
153
1001
1.93
8.20
3.8
3.1
39.55
49.80
e6/l
0.19
129
761
136
861
1.94
8.00
3.5
3.2
1171.53
1002.57
ng/l
0.30
119
719
239
1824
1.96
7.90
13.8
9.8
4.58
3.97
e9/l
2.69
220
1592
227
1706
1.92
7.82
9.6
6.4
0.19
0.19
e9/l
0.10
204
1489
58
267
2.40
7.75
2.7
2.4
10.65
10.40
g/l
0.17
50
246
26
77
3.57
7.68
5.1
2.2
7.41
7.42
ph
0.71
26
77
126
787
1.93
7.65
4.5
3.7
95.64
93.00
%
0.65
118
779
158
1064
1.88
7.61
3.7
3.3
2.34
2.35
mmol/l
0.79
149
967
219
1638
1.88
7.53
8.7
6.1
0.04
0.04
e9/l
0.26
192
1404
221
1664
1.87
7.37
8.8
6.2
1.94
1.95
e9/l
0.02
201
1464
218
1635
1.87
7.36
8.7
6.1
0.59
0.56
e9/l
1.09
191
1403
167
1154
1.85
7.33
4.6
3.7
66.86
98.69
e6/l
0.44
132
800
17
38
4.65
7.26
2.1
1.3
0.27
0.33
g/l
—
10
26
17
38
4.65
7.26
2.1
1.3
2.77
2.84
g/l
—
10
26
17
38
4.65
7.26
2.1
1.3
—
—
—
0
0
17
38
4.65
7.26
2.1
1.3
6.38
6.18
g/l
—
10
26
20
52
4.02
7.08
3.8
2.4
—
—
—
0
0
20
53
3.94
6.91
2.4
4.1
29.40
33.96
umol/l
0.50
15
46
17
41
4.31
6.62
1.9
2.0
—
—
—
0
0
69
364
2.11
6.62
2.1
2.6
6.07
7.34
umol/l
0.38
55
315
97
582
1.92
6.49
1.9
1.7
458.77
22941613.65
pmol/l
0.50
83
510
48
220
2.37
6.46
2.6
2.5
10.80
14.47
au/ml
—
5
19
181
1319
1.76
6.37
2.3
2.0
104.00
96.89
pmol/l
0.87
93
678
129
865
1.77
5.96
1.9
1.6
19.73
20.71
nmol/l
0.31
109
731
11
12
9.42
5.83
2.0
1.2
214.00
62.50
nmol/24h
1.12
11
12
197
1497
1.71
5.75
9.3
6.1
0.62
0.70
%
1.07
190
1402
17
46
3.83
5.71
3.1
2.1
7.20
6.10
pmol/l
0.45
17
46
50
246
2.20
5.70
6.3
4.4
7.39
7.34
ph
2.24
39
170
197
1505
1.70
5.57
9.4
6.1
8.42
8.77
%
1.16
190
1417
196
1499
1.69
5.49
9.2
6.0
2.70
2.79
%
0.27
189
1409
198
1520
1.69
5.46
8.7
6.0
57.72
57.12
%
0.30
192
1448
15
29
5.35
5.45
1.8
1.2
—
—
nmol/l
—
0
0
220
1737
1.70
5.45
5.4
3.6
0.02
0.01
estimate
0.17
55
310
8
5
16.31
5.43
1.0
1.0
5.99
6.66
mg/g
—
8
5
51
258
2.14
5.42
1.4
1.4
—
—
—
0
0
199
1533
1.68
5.38
9.1
6.1
27.52
28.14
%
0.31
192
1463
217
1717
1.68
5.24
5.6
3.6
0.00
4.91
estimate
0.50
59
331
185
1406
1.66
5.21
15.9
10.4
0.00
0.00
e9/l
0.79
150
1143
33
142
2.46
5.09
7.0
4.3
—
—
—
0
0
196
1521
1.65
5.01
3.8
2.9
120.96
106.30
ug/l
0.37
187
1427
156
1146
1.65
4.94
5.2
3.5
32.62
36.60
ng/l
0.15
123
761
108
721
1.72
4.92
1.9
1.7
1.17
1.20
mg/l
0.04
79
562
214
1707
1.64
4.83
5.4
3.6
0.00
0.00
estimate
0.50
54
327
139
996
1.65
4.83
2.8
2.3
—
—
—
0
0
132
940
1.64
4.67
6.2
3.7
0.00
0.01
estimate
0.99
56
309
12
22
5.61
4.64
1.1
1.2
0.57
0.46
ratio
—
6
9
321
2892
2.18
4.51
8.8
6.1
40.03
38.99
mmol/mol
0.93
309
2737
10
15
6.82
4.49
1.7
3.7
527.80
804.47
u/ml
—
10
15
319
2870
2.13
4.46
9.5
5.3
1.59
1.87
mu/l
2.79
289
2662
49
268
1.96
4.22
3.2
5.9
0.20
0.03
%
0.77
20
65
60
352
1.85
4.19
1.8
1.7
—
—
—
0
0
74
464
1.75
4.15
1.9
1.6
1205.43
1167.25
nmol/l
0.14
60
353
183
1439
1.56
4.13
3.2
2.7
—
—
estimate
—
0
0
169
1306
1.56
4.11
5.5
3.4
0.00
0.03
estimate
1.05
44
271
14
42
3.43
4.08
1.5
1.5
—
—
—
0
0
14
42
3.43
4.08
1.5
1.5
—
—
—
0
0
14
42
3.43
4.08
1.5
1.5
—
—
—
0
0
14
42
3.43
4.08
1.5
1.5
—
—
—
0
0
75
476
1.73
4.02
1.6
1.4
349.47
578.89
titre
1.28
19
108
36
181
2.10
3.90
2.5
3.0
80.52
150.44
ng/l
1.60
31
163
107
752
1.61
3.87
4.5
5.0
—
—
—
0
0
322
2943
2.04
3.73
6.8
5.0
5.96
5.89
mmol/l
0.38
307
2733
46
257
1.91
3.73
3.3
5.4
0.17
0.13
%
0.15
18
70
48
273
1.88
3.69
3.4
5.3
1.68
0.78
%
0.99
20
87
112
804
1.57
3.68
1.5
1.3
2.89
1.43
u/ml
0.46
25
230
11
25
4.51
3.65
1.5
1.2
—
—
—
0
0
46
259
1.89
3.64
3.2
5.0
0.77
0.49
%
0.59
22
79
173
1369
1.52
3.64
4.8
3.3
6.34
6.17
ph
1.20
97
775
7
9
7.91
3.57
2.0
1.9
15.94
19.74
umol/l
—
7
9
66
418
1.71
3.55
2.4
2.2
—
—
—
0
0
11
26
4.33
3.53
1.0
1.1
—
—
—
0
0
84
568
1.63
3.53
4.0
3.5
204.13
284.30
ng/l
0.29
53
416
139
1056
1.52
3.51
3.7
3.2
6.77
7.92
mmol/l
2.01
127
907
15
52
2.97
3.51
4.9
2.2
4.92
5.02
kpa
0.22
15
52
15
52
2.97
3.51
4.9
2.2
9.09
9.07
kpa
0.01
15
52
252
2174
1.55
3.43
4.8
3.3
45.03
46.15
u/l
0.10
239
2069
25
116
2.24
3.31
1.8
2.0
21.05
20.13
s
0.65
20
107
126
948
1.51
3.29
4.4
3.0
0.00
0.01
estimate
0.74
47
266
10
24
4.26
3.22
1.5
1.2
120.40
110.21
pmol/l
—
10
24
64
415
1.66
3.15
4.0
3.4
4.21
5.53
e9/l
0.77
52
373
128
976
1.49
3.10
5.0
4.1
9.55
9.66
mg/mmol
0.01
85
600
7
12
5.93
3.03
2.3
2.3
—
—
—
0
0
65
431
1.62
2.93
1.2
1.2
—
—
—
0
0
11
32
3.51
2.92
12.0
15.0
566.45
890.50
nmol/l
1.71
11
32
41
240
1.80
2.89
5.4
3.6
—
—
—
0
0
67
449
1.61
2.89
2.0
2.3
96.14
96.87
ug/g
0.01
51
356
27
137
2.05
2.89
2.2
2.3
—
—
—
0
0
70
475
1.59
2.87
4.0
2.8
3.01
2.67
e6/l
0.09
36
223
12
42
2.92
2.57
1.1
1.2
—
—
—
0
0
123
961
1.43
2.54
4.0
3.4
45.65
52.70
mg/l
0.12
87
613
24
123
2.02
2.52
1.1
1.3
—
—
—
0
0
327
3070
1.85
2.50
28.0
14.1
22.16
22.44
mg/l
0.06
286
2506
26
138
1.95
2.48
1.4
1.3
0.76
1.31
u/ml
—
8
8
9
27
3.39
2.41
1.8
1.3
1.61
1.35
promille
—
9
22
121
956
1.40
2.31
9.9
6.4
—
—
—
0
0
13
53
2.51
2.30
2.7
5.7
—
—
—
0
0
9
30
3.05
2.16
1.1
1.1
—
—
—
0
0
19
95
2.06
2.15
1.6
1.3
275.69
295.71
ug/g
0.18
13
54
94
720
1.42
2.12
1.6
1.4
2.06
2.39
g/l
1.29
64
446
12
49
2.50
2.12
1.2
1.1
46.60
8.90
iu/ml
—
5
10
9
31
2.95
2.08
1.1
1.2
—
—
—
0
0
100
778
1.40
2.06
2.8
2.8
356.65
337.31
umol/l
0.93
84
692
6
15
4.05
2.04
1.0
1.7
—
—
—
0
0
27
156
1.79
2.03
1.6
2.2
2.62
4.77
iu/ml
—
8
35
7
21
3.38
1.97
2.3
4.7
6.96
8.17
mmol/l
—
7
21
6
16
3.80
1.94
3.5
5.9
17.38
17.27
%
—
6
16
18
92
2.01
1.93
2.9
1.9
346.62
5.13
iu/l
—
9
41
31
190
1.69
1.92
1.8
2.5
—
—
—
0
0
56
396
1.49
1.92
2.0
1.5
—
—
—
0
0
99
781
1.37
1.86
6.0
3.5
1.01
1.02
kg/l
3.83
70
509
6
17
3.57
1.84
1.0
1.0
—
—
—
0
0
23
131
1.81
1.82
1.1
1.2
—
—
—
0
0
7
23
3.08
1.81
1.3
1.3
—
—
—
0
0
8
29
2.80
1.80
1.1
1.2
—
—
—
0
0
5
135
0.36
1.79
1.0
1.1
1.11
0.91
g/l
—
5
135
55
394
1.47
1.77
1.5
1.2
—
—
—
0
0
7
24
2.95
1.73
3.6
3.7
5.30
22.70
mg/l
—
7
19
0
48
0.00
1.71
0.0
1.0
—
2.68
—
0
25
10
40
2.54
1.68
1.2
1.2
—
—
—
0
0
14
69
2.07
1.67
2.4
2.4
45.71
91.39
ug/min
—
7
39
8
31
2.62
1.67
2.3
2.6
13.36
10.55
%
—
8
31
7
25
2.84
1.66
1.1
1.0
219.57
314.56
ng/l
—
7
16
5
133
0.37
1.65
1.0
1.1
1.66
1.57
g/l
—
5
133
37
249
1.54
1.60
1.6
1.5
—
—
—
0
0
8
32
2.53
1.60
1.8
2.6
—
—
—
0
0
6
20
3.03
1.58
1.3
1.9
8.55
11.94
umol/l
—
6
20
27
169
1.65
1.57
3.7
2.1
0.00
0.02
estimate
—
5
58
5
15
3.37
1.53
2.0
1.7
58.40
70.33
umol/l
—
5
15
0
44
0.00
1.52
0.0
1.1
—
7.23
—
0
17
28
182
1.58
1.42
1.1
1.2
—
—
—
0
0
18
104
1.77
1.39
9.0
9.6
—
—
—
0
0
6
23
2.64
1.37
1.0
1.0
—
—
—
0
0
40
285
1.45
1.35
1.2
1.2
—
—
—
0
0
11
54
2.07
1.34
1.2
1.2
11.48
12.89
u/l
0.19
11
47
5
18
2.80
1.29
1.0
1.5
135.40
138.28
nmol/l
—
5
18
66
519
1.33
1.26
1.9
1.6
—
—
—
0
0
6
25
2.42
1.25
2.3
3.0
—
—
—
0
0
26
172
1.55
1.24
1.4
1.5
0.17
0.33
mg/l
—
7
77
21
132
1.63
1.23
2.4
1.9
—
—
—
0
0
140
1217
1.25
1.23
2.5
2.1
—
—
—
0
0
95
792
1.27
1.18
5.5
4.9
2.79
2.17
ug/l
0.26
86
716
37
267
1.43
1.18
2.5
2.3
0.30
0.17
e6/l
0.47
32
252
32
225
1.46
1.17
1.1
1.2
78.51
145.47
u/ml
0.93
11
102
53
410
1.34
1.14
1.6
1.5
—
—
—
0
0
7
30
2.36
1.13
1.1
1.1
—
—
—
0
0
15
89
1.72
1.09
2.9
3.0
2.50
1.75
index
—
6
52
18
114
1.61
1.04
3.8
3.9
232.14
176.73
mg/l
—
7
49
41
309
1.37
1.04
3.2
2.0
0.00
0.05
estimate
—
9
66
9
48
1.90
1.01
3.7
2.8
4.61
4.56
e9/l
—
9
48
22
317
0.67
1.00
1.6
1.7
—
—
—
0
0
30
217
1.42
0.97
2.9
2.5
3.41
6.21
ug/l
1.91
24
195
6
27
2.24
0.94
1.5
2.0
44.38
40.06
%
—
6
27
15
96
1.59
0.85
1.1
1.1
—
—
—
0
0
30
224
1.37
0.83
1.4
1.3
78.75
394.87
u/ml
1.71
30
206
29
216
1.37
0.82
1.2
1.2
—
—
—
0
0
302
2908
1.26
0.81
5.1
4.2
1.40
1.30
mmol/l
1.47
285
2701
252
2644
0.84
0.77
37.0
18.3
331.07
332.72
g/l
1.88
252
2635
115
1285
0.84
0.77
4.2
3.1
—
—
—
0
0
5
24
2.10
0.75
1.2
3.3
2593.40
1036.71
mg
—
5
24
34
266
1.31
0.71
3.6
2.3
6.21
6.13
ph
0.20
21
169
13
85
1.55
0.70
2.1
1.9
—
—
—
0
0
14
203
0.68
0.69
1.8
1.6
—
—
—
0
0
9
59
1.54
0.69
1.0
1.1
—
—
—
0
0
7
42
1.68
0.68
3.6
3.3
0.29
1.23
%
—
7
37
7
42
1.68
0.68
1.6
1.2
—
—
—
0
0
325
3172
1.30
0.65
26.7
12.4
—
—
—
0
0
5
30
1.68
0.61
1.0
1.6
33.20
32.37
pg
—
5
30
11
72
1.54
0.59
1.1
1.7
—
—
—
0
0
75
657
1.18
0.59
1.5
1.3
17.46
32.05
iu/ml
1.93
27
194
10
65
1.55
0.56
1.0
1.6
—
—
—
0
0
147
1367
1.13
0.51
1.9
1.9
1.50
1.37
mmol/l
1.18
126
1174
5
31
1.62
0.43
1.6
2.6
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.5
—
89.82
—
0
11
15
115
1.32
0.39
1.0
1.4
139.90
265.14
miu/ml
—
8
61
5
37
1.36
0.37
1.4
2.6
1.19
1.19
mmol/l
—
5
37
5
37
1.36
0.37
1.4
2.6
105.80
106.43
mmol/l
—
5
37
5
37
1.36
0.37
1.4
2.6
3.88
4.02
mmol/l
—
5
37
6
43
1.40
0.35
1.2
1.2
—
—
—
0
0
66
601
1.12
0.33
2.1
1.9
—
—
—
0
0
12
154
0.77
0.32
1.5
1.5
—
—
—
0
0
7
96
0.72
0.31
1.0
1.2
—
—
—
0
0
35
392
0.88
0.26
1.3
1.5
—
—
—
0
0
9
72
1.26
0.26
3.7
2.6
61.56
57.42
%
—
9
72
29
327
0.88
0.24
3.5
4.5
3.50
41.15
ug/l
0.91
23
270
5
38
1.32
0.23
1.0
1.1
—
—
—
0
0
309
3050
1.10
0.21
6.0
5.0
4.58
4.72
mmol/l
1.77
294
2871
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
65
607
1.09
0.21
1.6
1.3
3.33
10.20
u/ml
1.68
30
248
308
3042
1.10
0.20
6.0
4.9
1.40
1.48
mmol/l
2.58
292
2845
12
99
1.22
0.20
1.3
1.2
—
—
—
0
0
6
51
1.18
0.19
1.0
1.0
—
—
—
0
0
7
58
1.21
0.18
1.3
1.5
—
—
—
0
0
14
119
1.18
0.18
1.6
1.6
10.00
10.04
u/ml
—
5
27
22
196
1.13
0.17
1.2
1.1
—
—
—
0
0
8
69
1.16
0.16
5.4
4.2
—
—
—
0
0
9
80
1.13
0.15
2.1
1.2
—
—
—
0
0
95
916
1.05
0.13
1.4
1.4
—
—
—
0
0
38
355
1.08
0.13
1.3
1.3
—
—
—
0
0
12
105
1.15
0.11
2.0
2.9
—
—
—
0
0
5
48
1.04
0.09
1.0
1.1
—
—
—
0
0
14
154
0.91
0.08
1.4
1.5
—
—
—
0
0
14
154
0.91
0.08
1.4
1.5
—
—
—
0
0
311
3093
1.05
0.07
6.8
5.7
2.69
2.78
mmol/l
0.93
297
2897
14
151
0.92
0.05
1.4
1.5
—
—
—
0
0
37
357
1.04
0.05
1.6
1.5
—
—
—
0
0
12
111
1.08
0.04
1.3
1.4
—
—
—
0
0
46
472
0.97
0.03
3.4
2.8
1.01
0.75
ug/l
0.27
38
281
334
3347
0.96
0.01
45.4
22.1
134.49
136.36
g/l
1.66
334
3319
334
3346
0.97
0.00
46.1
22.4
52.49
40.74
%
0.48
334
3317
334
3346
0.97
0.00
44.8
21.8
30.16
30.30
pg
0.73
334
3320
14
145
0.96
0.00
1.1
1.5
—
—
—
0
0
334
3345
0.97
0.00
44.9
21.9
90.97
90.87
fl
0.15
334
3319
16
156
1.03
0.00
1.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
53.33
—
0
6
0
6
0.00
0.00
0.0
1.3
—
1.74
—
0
6
0
6
0.00
0.00
0.0
3.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.1
—
37.50
—
0
8
12
120
1.00
-0.00
1.1
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
6.3
—
7.63
—
0
8
0
8
0.00
-0.00
0.0
5.1
—
48.06
—
0
8
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint E4_DIABINSIPIDUS and mortality.

Females

Parameter HR [95% CI] p-value
E4_DIABINSIPIDUS 3.239 [2.46, 4.27] < 0.001
Birth year 1.001 [0.99, 1.01] 0.864

During the follow-up period (1.1.1998 — 31.12.2019), 127 out of 716 females with E4_DIABINSIPIDUS died.

Males

Parameter HR [95% CI] p-value
E4_DIABINSIPIDUS 2.412 [1.78, 3.27] < 0.001
Birth year 0.988 [0.98, 1.0] 0.015

During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 595 males with E4_DIABINSIPIDUS died.

Mortality risk

Mortality risk for people of age

years, who have E4_DIABINSIPIDUS.

N-year risk Females Males
1 0.39% 0.489%
5 2.107% 3.104%
10 5.629% 7.422%
15 10.58% 13.857%
20 18.654% 22.663%

Relationships between endpoints

↥

Index endpoint: E4_DIABINSIPIDUS – Diabetes insipidus

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data